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Abstract
Porcine reproductive and respiratory syndrome (PRRS) causes significant economic losses due
to reproductive failure and respiratory disease. The high genetic and antigenic diversity of
PRRSV makes the control of this disease very challenging. Current vaccines cannot provide
adequate protection to the circulating PRRSV strains; therefore, vaccines can confer crossprotection are in urgent demand. Two T-cell mosaic vaccines were designed based on 748 GP5
sequences using the Mosaic T-Cell Vaccine Tool Suite from the Los Alamos National
Laboratory. These mosaic sequences were then used to construct DNA vaccines. Significantly
higher levels of interferon-γ mRNA and virus-specific antibodies, rapid virus clearance in sera
and systemic tissues such as spleen and ILN, lower lung lesion scores were recorded in GP5Mosaic-vaccinated pigs suggested that the GP5-Mosaic vaccine was immunogenic and induced
partial protection. The GP5-Mosaic vaccines complexed to cationic liposomes were administered
by intramuscular injection and boosted three times at days 14, 28 and 42. Significantly higher
levels of IFN- γ mRNA were detected in PBMCs of GP5-Mosaic-vaccinated pigs stimulated by 4
Genotype II PRRSV strains including VR2332, NADC9, NADC30, and SDSU73; while such
responses were recorded only upon VR2332 stimulation in GP5-WT-vaccinated pigs. Pigs
receiving the GP5-Mosaic vaccine were partially protected as indicated by significantly lower
viral loads in sera, tissues, and lower lung lesion scores. At last, where priming with an rDNA
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GP5-Mosaic and boosting with a recombinant Tet inducible Vaccinia virus GP5-Mosaic
followed by heterologous virus challenge trial was performed in pigs. Similar results were
recorded as GP5-Mosaic vaccination induced both humoral and cellular responses. Furthermore,
the GP5-Mosaic-vaccinated pigs were cross-protected from heterologous strains as indicated by
significantly lower viral loads in sera, tissues, porcine alveolar macrophages, and
bronchoalveolar lavage fluids as well as lower lung lesion scores against either MN184C or
VR2332 challenge. Under the same criteria, pigs receiving the GP5-WT vaccination showed
higher protection only against challenge with VR2332 when compared to the vector-control
group.
Overall, this dissertation reported a viable approach, GP5-Mosaic T-cell DNA vaccines, to
address PRRSV diversity issue as capable of inducing both humoral and cellular responses thus
providing cross-protection against heterologous PRRSV strains in pigs.
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Chapter I Introduction

1. PRRS Overview
Porcine reproductive and respiratory syndrome (PRRS)
Porcine reproductive and respiratory syndrome (PRRS) is a major disease affecting the swine
industry worldwide. PRRS causes significant economic impact with estimated annual losses of
more than 600 million dollars in the United States (1) and up to 1 billion dollars elsewhere. The
disease is characterized by reproductive failure in sows and frequently fatal respiratory disease in
young pigs (2)(3).

History and global distribution
PRRS was first recognized as a major cause of reproductive losses and respiratory diseases in the
United States in the mid-1980's and named "mystery swine disease" or “mystery reproductive
syndrome”. The causative agent, PRRS virus (PRRSV) was initially isolated in the Netherlands in
1991 (4) and one year later in the United States (5). The virus isolates from the Netherlands
(Lelystad virus), and the United States (VR2332) are the reference strains of the European type
(type I) and the American type (type II), respectively. Currently, type I is more prevalent in Europe,
whereas type II is dominantly prevalent in the United States, Canada, and Asian countries.
Nonetheless, it is believed that PRRSV is present in most swine-producing regions of the world,
with a few exceptions such as Switzerland, Sweden, Norway, Finland and Australia. Within
infected regions, it is estimated that 60-80% of herds are typically infected.
In 2006, a highly pathogenic strain of type II PRRSV (HP-PRRSV) emerged in China (6) and
spread to other Southeastern Asian countries.
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Virion structure
PRRSV has been classified as a member of the family Arteriviridae, in the order of Nidovirales
(7)(8). PRRSV has a single-stranded, positive-sense RNA as genome that varies in length (14,876–
15,520 bp). The virions are roughly spherical with an average diameter of 54 nm and consist of a
nucleocapsid surrounded by a lipid bilayer containing several proteins (9)(10) PRRSV has 10 open
reading frames (ORF) which encode 8 structural proteins and at least 14 non-structural proteins
(nsp) (Fig.1(11)).

Figure 1.1 Schematic genome of PRRSV
Non-structural proteins (nsps) encoded by ORFs 1a and 1b, which constitute almost two-thirds of
the genome, (such as RNA replicase and helicase), that are required for virus replication (12). At
least 14 nsps are generated as a result of translation by a ribosomal frame shift between ORF1a
and 1b (8)(13). Three N-glycosylated minor envelope proteins (GP2a, GP3, and GP4) are encoded
by ORF2a, ORF3, and ORF4 and form heterotrimers by disulfide bond (14). This protein complex
is responsible for virion attachment and entry by binding to CD163 (15). ORF2b, which is derived
from a different frame within ORF2a, encodes another non-glycosylated minor protein named E
(16). ORF5 encodes the major envelope glycoprotein (GP5) that forms a heterodimer with the
membrane non-glycosylated protein (M) encoded by ORF6 which also participates in virion
attachment by interacting with CD169 (17). The viral capsid is composed of only one nucleocapsid
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protein (N), which is encoded by ORF7 and is highly immunogenic in infected animals (18). For
all the major PRRSV viral proteins including structural and non-structural proteins, their
characteristics and functions are summarized in Table 1 (adapted from (19)).

PRRSV replication
The PRRSV replication cycle is summarized in Figure 1.2 (11). Briefly, virus particles bind

Figure 1.2. Overview of PRRSV replication (11)
to the cellular receptors and are then internalized by receptor-mediated endocytosis. After entry
and uncoating, the positive-sense genomic RNA is released and subsequently acts as mRNA for
synthesis of nsp polyprotein complexes polyprotein-1a and polyprotein-1b, which undergo
3

cleavage by viral proteases to produce 13-14 nsps. The nsps assemble into a replication and
transcription complex (RTC) to catalyze replication of genomic RNA to produce full-length
antigenomic RNA from which a nested transcription to produce 6 sub-genomic sense RNAs (sg
mRNAs). The different sg mRNAs are translated to produce 7 structural proteins – GP2 2b, GP3,
GP4, GP5, M, and N. All the structural proteins are required for viral packaging. Ultimately, newly
synthesized genomes are packaged into nucleocapsids and then become enveloped. This assembly
process occurs in the ER and Golgi complex. Budding of progeny virus occurs in the membranes
of the endoplasmic reticulum and Golgi complex followed by exocytosis and the subsequent
release of the enveloped virion particle.

Pathogenicity of the PRRS virus
It has been reported that PRRSV has a very restricted cell tropism both in vitro and in vivo. PRRSV
was originally isolated in primary cell cultures of porcine alveolar macrophages (PAMs) (4) and
to date, differentiated monocytes, along with PAMs, are the only porcine cells that can be
effectively used for virus propagation. In addition, MARC-145 and CL2621 cells that are
subclones of MA104 are also commonly used for propagating PRRSV in vitro. In vivo, the primary
target cells of PRRSV are PAMs in the lung, interstitial macrophages, and those found in the heart,
spleen, thymus and Peyer’s patches. The clinical signs of PRRSV are reproductive failure in sows
and often fatal respiratory disease in young pigs. PRRSV infection in sows can cause severe
reproductive problems including premature farrowing, litters with weak, stillborn or mummified
offspring and delayed return to service (20). In the United States, there were increased outbreaks
later described as atypical PRRS or “swine abortion storm” (21). The spontaneous abortion rate
was up 10-50%, and the mortality rate of the breeding herd has been found to be up to 5-10%
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during an outbreak (22). In young pigs, they can display a variety of clinical signs such as dyspnea,
tachypnea and death (up to 100% mortality). There were major outbreaks related to Isolates 184,
RFLP 1-8-4 or Strain MN184 in 2001 and 2006 (23)(24). These outbreaks caused high morbidity
(50%) and mortality (20%) rates. The analysis of ORF5 nucleotide sequence and comparison with
other type 2 PRRS virus strains, demonstrated that MN184 was significantly different to previous
strains. Also, three highly variable regions were identified, corresponding to nsp1β, nsp2, and
ORF5. Nsp2 shared only 66-70% amino acid similarity to other North-American PRRS virus nsp2
proteins.
Table 1.1 PRRSV structural and non-structural proteins major characteristics and
functions
Proteins

Genes

Nsp1

ORF1a

Nsp2

Nsp9

No. of
AA(NA)
383
980

ORF1b

640

Nsp10
Nsp11
GP2a

ORF2a

256

E

ORF2b

73

GP3

ORF3

254

GP4

ORF4

178

Characteristics and functions
Non-structural multifunctional regulatory protein; proteolytic
activities; IFN inhibition
Non-structural, the largest PRRSV replicative protein; the major
genetic differences between NA and EU strains; ideal marker
for monitoring genetic variation and for developing differential
diagnostic tests; proteolytic activities; IFN inhibition
Non-structural proteins; virus transcription and replication;
nsp9: RNA-dependent RNA polymerase and NTPase; nsp10:
helicase; nsp11: IFN inhibition

441
Minor structural protein; contains 2 highly conserved N-linked
glycosylation sites; essential for virus infectivity; incorporated
into virions as a multimeric complex; viral attachment protein
Minor unglycosylated structural protein; essential for virus
infectivity; incorporated into virions as a multimeric complex
Minor structural protein, one of the most variable PRRSV
proteins; highly glycosylated with 7 N-linked oligosaccharides;
highly antigenic and may be involved in viral neutralization;
essential for virus infectivity; incorporated into virions as a
multimeric complex
Minor structural highly glycosylated protein (4 sites); essential
for virus infectivity; key glycoprotein for formation of the
multiprotein complex incorporated into virions; mediates
interaction between the complex and GP5; viral attachment
protein and may be involved in viral neutralization

5

GP5

ORF5

200

Major structural, transmembrane protein with a variable number
of potential N-glycosylation sites; the most variable structural
protein in the PRRSV genome with GP3; involved in virus
neutralization and protection; the covalent association of GP5
and M protein is crucial for virus assembly viral attachment
protein; involved in the entry of virus into the host cells and in
the apoptosis process
M
ORF6
174
Major unglycosylated structural protein which is the most
conserved; play a key role in virus assembly and budding; GP5M heterodimerization is crucial for virus infectivity
N
ORF7
123
Major unglycosylated, phosphorylated and structural protein;
highly immunogenic and a suitable candidate for the detection
of virus-specific Abs and diagnosis of the disease; the sole
component of the viral capsid and interacts with itself through
covalent and non-covalent interactions; able to localize in the
nucleus and interact with cellular transcription factor
ORF, open reading frames; EU, European PRRSV strains; NA, North American PRRSV strains

In 2006, highly pathogenic PRRS (HP-PRRS) outbreaks provoked high losses to the pig
production in China and later spread to other Asian countries. The causative agent of HP-PRRS
was characterized as a variant of NA-PRRS virus (PRRSV) with a higher pathogenicity/virulence,
which is called HP-PRRSV (6). The HP-PRRSV infection showed more severe reproductive
failures in pregnant sows, higher morbidity (usually 50%-100%), and the mortality rates ranged
from 20% to 100% in pigs of all ages. More than 40% of the infected pregnant sows exhibited
abortions. All the infected pigs displayed a high fever of over 41°C. Total mortality rates were
recorded in Laos, and they ranged from 6.02% in boars to 91.28% in piglets.

PRRSV infection and immune responses
Host innate immune responses play an instrumental role against early viral infection. Especially,
type I IFNs are a critical component of the innate immunity against viral infections and play an
essential role in the induction of adaptive immunity (25)(26). PRRSV sensitivity to type I IFNs
was demonstrated in a study where IFN-α had the ability to reduce lung lesions and delay viremia
in pigs (27). Some of the PRRSV proteins including nsp1, nsp2, nsp11, and N are found to inhibit
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IFN induction and IFN signaling pathways (28). nsp1α and nsp1 were shown to inhibit IFN-,
specifically expression (29)(30).

Figure 1.3 Immune responses to PRRSV infection (from Lopez et al.)
In another study, a strain dependent inhibition or activation of type I IFNs and IFN-induced
proteins such as Mx-1 was reported (31). IFNs bind to their receptors on the cell surface and
activate JAK/STAT pathway, leading to the expression of IFN-stimulated genes (ISGs) in both
MARC-145 cells and PAM cells (32)(33)(34).
There is evidence that PRRSV infection results in delayed immune responses (Fig.1.3(35)). Viral
neutralizing (VN) antibodies are usually not detected until four weeks post-infection (36)(37), and
they peak at 10-18 weeks post-infection with relatively low titers (37)(38). GP5 contains the most
critical neutralizing epitope, yet the presence of multiple glycosylation sites might interfere with
the access of antibodies to GP5. Moreover, the existence of a decoy epitope on GP5 that induces
non-neutralizing antibodies with a delayed production of VN antibodies for at least three or four
weeks (39). Some studies have shown that viremia may be resolved before the presence of VN
7

antibodies (38). Other evidence supports that VN antibodies are important for protection, although
the mechanism of action remains unclear (40)(41)(39)(42)(43). In PRRS, prolonged viremia
correlates with a weak innate antiviral response (32)(28), high levels of IL-10 and TGF (44), low
levels of IFN-γ coupled to sub-optimal adaptive immunity (45)(39). A study also showed that the
levels of IFN-γ and IL-10 were satisfactory markers of polarization of the adaptive response, and
the level of IL-10 correlated directly with the level of infected macrophages (46).
The adaptive cellular response can be assessed by lymphocyte recall stimulation (47) and detection
of antigen-specific cytotoxic T lymphocytes (CTL). Several studies have shown that cell-mediated
immune responses are weak and delayed in PRRSV-infected pigs (45). In addition, IL-10 can
induce regulatory T cells that may down-regulate the production of IFN-γ producing cells, result
in the shift of Th1 response to Th2 response (48)(49)(50).

2. Vaccine Design Strategy
Next Generation Vaccine Technologies
The control of PRRS relies largely on vaccination with conventional modified live-attenuated
vaccines and killed vaccines. Additionally, some local farm-specific autogenous vaccines are used
in the United States (51). Since the protection by current vaccines is limited to homologous
PRRSV strains, the demand for vaccines that protect against diverse strains is very high.
Unfortunately improving vaccine coverage is difficult due to the vast genetic and antigenic
diversity of the virus. Next generation vaccine strategies that increase both breadth and depth for
highly variable viruses such as consensus sequence vaccines, multi-subunit vaccines, molecular
breeding by DNA shuffling and screening strategies for PRRSV, and mosaic T-cell epitope
vaccines are being intensively investigated (52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62). Mosaic
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T-cell epitope vaccines can be generated using a Mosaic Vaccine Tool Suite that was originally
designed to address HIV sequence diversity at Los Alamos National Laboratory (61). Briefly, the
resulting mosaic sequences are generated from in silico “recombination” of natural strains of virus
and are constrained in the same fashion as natural virus sequences. Studies show that these Mosaic
T-cell epitope vaccines improve the immune responses to the globally circulating strains of HIV1 by broadening the range of recognized epitopes and increasing responses to high-frequency
epitopic variants (63)(64).

Mosaic Vaccines
A mosaic protein, is a recombinant protein derived from a library of proteins of interest through

Figure 1.4. The process of generation of mosaic sequences (courtesy of Caitlin O’Connell)

many cycles of recombination. As the building blocks for the mosaic protein, (N-mer) peptides
that make up the mosaic sequence by overlapping each other exit naturally within the protein
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library. Values of N between 9 and 12 are recommended because that is the size of peptides
preferentially recognized by cytotoxic T-cells (Figure 1.4).

Potential T cell epitope targets on PRRSV
There are more than a dozen T-cell epitopes that have been identified in several viral proteins of
PRRSV including non-structural proteins nsp2, nsp9 and nsp10, structural proteins GP5, M and
the capsid protein N which have been reported by different research groups (Table 1.2). Among
these proteins, nsp2 and nsp10 are excluded due to their ability to suppress the host immune
Table 1.2 T cell epitopes identified on PRRSV

response. GP5 is the perfect candidate based on the fact that it has two reported T-cell epitopes
(65)(66) and a major neutralizing epitope (39)(67). It forms a heterodimer with M protein, and
together they play a vital role in virus infectivity. GP5 is highly variable and thus it is a major
target for phylogenic analysis and vaccine development. Additionally, the most extensive sequence
10

information on hand is for GP5. Combining what is known at this time, we believe that GP5 is our
best choice as a candidate to develop mosaic T-cell epitope vaccine to address the diversity issue
of PRRSV. A method that is readily available for rapid vaccine evaluation is the use of expression
plasmid DNA as the backbone to deliver and test viral antigens.

3. DNA Vaccine
DNA vaccine plasmid
DNA vaccination induces immune responses to protein(s) of interest expressed in vivo following
the introduction of DNA plasmid encoding the protein sequence of candidate antigens (68).
Normally, the target protein is expressed under a strong promoter such as human
cytomegalovirus (CMV) as it activates high levels of transgene expression in vivo hence
facilitating antigen presentation (69). The vaccine plasmids are readily produced in bacterial
culture, purified, quantified, formulated when necessary and then used as a vaccine.

Advantages of DNA vaccine
DNA vaccines have several notable advantages over traditional vaccination strategies such as
modified-live virus and killed virus vaccines. 1) As a safe, non-living vaccine approach, DNA
vaccines have no risk of infection. 2) Target antigen can be presented by both class I and class II
major histocompatibility complex (MHC) molecules. As a result, both CD4+ and CD8+ T cell
responses are generated. Therefore, DNA vaccines can induce both humoral (70) and cellmediated immune responses (CMI) (71), 3) The relative ease of DNA vaccine design and
production allows for the quick and efficient development of immunogens via recombinant DNA
technology. 4) DNA vaccines are also stable and can be used with multiple immunizations. Lastly,
11

5) In vivo expression ensures protein more closely resembles normal eukaryotic structure, with
accompanying post-translational modifications and both cytosolic sand endosomal processing and
presentation.

Mechanism of DNA Vaccination
The mechanism by which DNA vaccines induce adaptive immune responses has been well studied.
The gene of interest can be delivered either intradermally, subcutaneously, or directly into muscle

Figure 1.5. Mechanisms of action of DNA vaccines (72)
by different delivery methods including gene gun, electroporation, or needle-free injection
systems. It is widely recognized that local myocytes and keratinocytes, including resident APC
populations, can be directly transfected by DNA vaccines or enter via either phago- or pinocytosis
(73). Facilitated by host cellular machinery in the nucleus, the gene of interest is transcribed and
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translated (74). This process is then sequentially followed by the expression of polypeptides, and
finally, by processing and presentation on MHC I or MHC II molecules, depending on whether
the antigen is transported endogenously or exogenously. Later in the immune response, mature
antigen presenting cells (APCs) travel to the draining lymph nodes where they encounter and
stimulate naive T-cells (73). This process also provides the secondary signals that are essential to
initiate an immune response, facilitating T-cell activation, either towards Th1 or Th2, which
subsequently activates cytotoxic T cells or B cells and antibody production cascades (Figure 1.5,
(72)).
In this manner, DNA vaccines are capable of inducing both humoral and cellular immune
responses. The successful expression of antigen in vivo is very crucial in conferring protective
immunity following DNA vaccination. Antigen is produced directly and naturally by host cells,
and thus allows target proteins to undergo well-regulated translation processes, which facilitate
correct conformational folding, along with post-translational modifications, such as glycosylation.
This assures accurate mimicking of natural pathogen infection without possible safety risks
(75)(76). Furthermore, plasmid DNA contains unmethylated deoxycytidylate-phosphatedeoxyguanylate (CpG) motifs, which have shown to be able to activate APC populations, thus
increasing their ability to stimulate antigen-specific CD4+/CD8+ T cells, which result in enhanced
immune responses.
4. Hypothesis
Our hypothesis is that mosaic T cell vaccines can present a wide array of T cell epitopes
representing many PRRSV strains, which can increase the breadth and depth of immune
recognition and ultimately broaden the protection against divergent PRRSV strains.
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5. Project Overview
This project includes the collection of ORF5 sequence information, generation of GP5-Mosaic
sequences, construction of GP5-Mosaic vaccine, characterization of the GP5-Mosaic vaccines,

Figure 1.6 Project Overview
and antigen expression in vitro. The second step was to test the immunogenicity of the GP5-Mosaic
vaccines in pigs. Three vaccination/challenge trials were conducted using different delivery
systems such as gene gun, electroporation or liposomes. In the first two trials, the experimental
pigs were challenged with VR2332 to evaluate the efficacy of the GP5-Mosaic vaccine. Their
capability to induce cross reactivity ex vivo was tested by stimulation of PBMCs and expression
of IFN-γ. The final trial tested the ability of the GP5-Mosaic vaccine to confer cross protection in
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pigs. For this purpose, the experimental pigs were challenged with two PRRSV strains which have
more than 10% difference in GP5 sequence VR2332 and MN184C (shown in Figure 1.6).

6. Summary
This thesis tested the ability of a GP5-Mosaic T-cell vaccine generated using a Mosaic Tool Suite
that was originally developed for HIV-1 in Los Alamos National Laboratory, to cross-protect pigs
from heterologous virus challenge. The characterization of GP5-Mosaic sequences, the evaluation
of immunogenicity and protection in pigs, the ability to induce cross-reactivity ex-vivo, and
eventually the efficacy against heterologous PRRSV challenge are discussed.
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Chapter II A GP5 Mosaic T-cell Vaccine for Porcine Reproductive and Respiratory
Syndrome Virus Is Immunogenic and Confers Partial Protection to Pigs

Summary
Porcine reproductive and respiratory syndrome (PRRS) causes significant economic losses due
to reproductive failure and respiratory disease. The high genetic and antigenic diversity of the
causative agent PRRSV, an RNA virus, makes the control of this disease very challenging. In
order to achieve broad protection towards such a divergent virus, two T-cell mosaic vaccines
were designed based on 748 glycoprotein 5 sequences using the Mosaic T-Cell Vaccine Tool
Suite from the Los Alamos National Laboratory. Mosaic sequences were then used to construct
two DNA vaccines. The mosaics were closer in amino acid sequence to strains that differ from
VR2332 by at least 10%. The T-cell epitope coverage was broadened when two mosaics were
made. Expression of the mosaic sequences was verified in E. coli BL21 (DE3) by western blot.
Two vaccination/challenge trials were performed in pigs to evaluate immunogenicity. The
vaccines were delivered by gene gun (Trial 1) or electroporation (Trial 2). Significantly higher
proliferative responses were detected in virus-stimulated peripheral blood mononuclear cells of
GP5-Mosaic-vaccinated pigs compared to control pigs in both trials. In Trial 2, significantly
higher levels of interferon-γ mRNA and lower levels of IL-10 mRNA were detected in GP5Mosaic-vaccinated pigs, as compared to control pigs. Virus-specific antibodies were higher in
GP5-Mosaic-vaccinated animals than in control animals in Trial 2. The antibodies were
neutralizing. In Trial 2, the viral copy numbers in serum 5 days after challenge with VR2332
decreased over 260-fold within 2 days in GP5-Mosaic-vaccinated pigs, while the viral copy
numbers increased by 1.2 to 5-fold in control animals in the same period. In Trial 2, viral loads
in inguinal lymph nodes and spleen, and lung lesion scores of GP5-Mosaic-vaccinated animals
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were lower compared to those of control animals. This data led us to conclude that the GP5Mosaic vaccine was immunogenic and induced partial protection in vaccinated pigs.

Key words: PRRS, PRRSV, mosaic T-cell vaccine, swine

1. Introduction
Porcine reproductive and respiratory syndrome (PRRS) is a major disease affecting swine
worldwide, characterized by reproductive failure and respiratory disease (1)(2). PRRS causes a
significant economic impact, with annual losses of more than 660 million dollars in the United
States alone (3). PRRSV, the causative pathogen, , is a member of genus Arterivirus, family
Arteriviridae, order Nidovirales (4)(5). The genome is a single-stranded, positive sense RNA and
the virion has an envelope. The viral genome is approximately 15 kb, and encodes 7 structural
proteins and 14 non-structural proteins (6)(7)(8)(9). Among the structural proteins, ORF5 is
attractive in diversity-related studies due to its great variability (10)(11)(12)(13)(14). ORF5
encodes for GP5, an envelope protein containing a major neutralizing epitope (15)(16) and at
least two T-cell epitopes (17)(18). GP5 forms a heterodimer with the M protein, which plays a
role in viral infectivity and assembly (19). GP5 is of major interest in vaccine studies
(20)(21)(22)(23)(24)(25)(26)(27). There are two main genotypes, Genotype I (European type)
and Genotype II (North American type) (28). Nucleotide dissimilarity between genotypes of up
to 40%, and within the same genotype up to 20% have been recorded (29). This high genetic and
antigenic diversity is a major challenge for control of PRRS.
The control of PRRS relies largely on vaccination with modified-live-attenuated vaccines
and killed-virus vaccines. Additionally, autogenous vaccines are used (30). Next generation
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vaccine strategies to increase both breadth and depth for highly variable virus include consensus
sequence vaccines (31)(32)(33), multisubunit vaccines (34)(35)(36)(37), molecular breeding by
DNA shuffling (38)(39)(40)(25) and mosaic T-cell epitope vaccines (41)(42)(43)(44)(45)(46).
The latter, a mosaic protein, is a recombinant protein derived from a collection of protein
sequences of interest. As building blocks for the mosaic protein, each and every peptide (N-mer)
can be found naturally within the input proteins. Values of N between 9 and 12 are
recommended because that is the size of peptides preferentially recognized by cytotoxic T-cells.
A Mosaic Vaccine Tool Suite originally designed to develop HIV mosaic vaccines at Los
Alamos National Laboratory (Los Alamos, NM) (41) is available. Studies show that these
mosaic T-cell epitope vaccines improved the immune responses to globally circulating strains of
HIV-1 by broadening the range of recognized epitopes and increasing responses to highfrequency epitopic variants (44)(45). Considering the variability similarities with HIV, a mosaic
T-cell vaccine for PRRSV could represent many divergent strains and induce broad T-cell
responses. The T-cell vaccine concept does not exclude the simultaneous use of vaccine
components that activate humoral protective immunity. Two mosaic T-cell epitope DNA
vaccines were developed based on GP5 sequences of 748 Genotype II strains. Two
vaccination/challenge trials in pigs were conducted and the results are discussed.

2. Materials and Methods
2.1. Viruses and Cells
VR2332 was propagated in MARC-145 cells. The cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM Lglutamine, 100 U penicillin/mL, and 100 µg streptomycin/mL. The virus was purified over
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continuous cesium chloride gradients, quantified using a spectrophotometer NanoDrop 1000
(Thermo Scientific) and stored at -80°C for future use. Purified virus was used as antigen for
indirect ELISA and lymphocyte proliferation assays.

2.2. Design and Construction of Mosaic T-cell DNA Vaccines
GP5-Mosaic sequences were designed using the Mosaic T-Cell Vaccine Tool Suite (Los
Alamos National Laboratory) (32)(41). Genotype II ORF 5 sequences were obtained from the
following sources: 67 sequences from GenBank, 678 sequences, courtesy of Dr. Fred Leung,
University of Hong Kong, and 3 full-length genome sequences, courtesy of Dr. Kay Faaberg,
USDA ARS. Based upon the coverage assessment tools provided in the Mosaic T Cell Vaccine
Tool Suite, two mosaic outputs were selected that maximized the 9-mer epitope coverage.
Porcine codon-optimized mosaic sequences with additional 3’ polyhistidine tags were
synthesized by DNA 2.0 (Menlo Park, CA) and subcloned into the Xho and Eag sites of plasmid
phCMV1 (Genlantis, San Diego, CA), under the control of the CMV promoter (shown in
Scheme 2.1). Plasmid DNA was purified using the Plasmid Giga Kit as instructed (Qiagen,
Valencia, CA).

2.3. Characterization of GP5-Mosaic Sequences
2.3.1. Matched 9-mer Coverage by Position and Epitope Coverage Assessment
Alignment of 748 GP5 sequences is color coded according to potential 9-mer
epitope coverage by the two designed mosaic sequences using the Posicover tool
(41)(42). Mean per sequence coverage of 748 PRRSV GP5 sequences by 2
designed mosaic sequences was analyzed using the Epicover tool (41) (42).

28

2.3.2. Comparison of GP5-Mosaic Sequences with Divergent PRRSV Strains
The homologies between GP5 sequences of VR2332, NADC9, NADC30, SDSU73,
MN184(C), Mosaic1 and Mosaic2 were evaluated using BLAST (NCBI, Bethesda,
MD).
2.3.3. Western Blot
Expression of protein by the mosaic constructs was verified in Escherichia coli
BL21 (DE3). Briefly, transformed BL21 cells were cultured in LB broth containing
kanamycin. Cell lysates were resuspended in 2x Laemmli sample buffer with 5% mercaptoethanol (Sigma, St. Louis, MO), boiled for 5 min and subjected to SDSPAGE on 10% gels. Proteins were transferred onto PVDF membranes, and blocked
for 2 h with 5% (w/v) dry milk in 0.05% (v/v) Tween 20/Tris-buffered saline (TTBS). The blots were probed with a PRRSV-positive swine serum pool for 2 h at
room temperature. After washing, HRP-conjugated anti-pig IgG antibody (Santa
Cruz Biotechnology, Dallas, TX) was added and incubated for 2 h, then washed four
times (10 min each) with T-TBS. Proteins were demonstrated by
chemiluminescence (GE Health, Marlborough, MA).

2.4. Vaccination and Collection of Samples

Three to four week-old, PRRSV-free, porcine circovirus-2-free, cross-bred piglets were
utilized in the study. The vaccines were administered by gene gun or electroporation as described
in Table 2.2. Briefly, in Trial 1, DNA vaccine coupled to 1 µm gold beads was administered with
a Helios Gene Gun (Bio-Rad Hercules, CA) at day 0 and boosted at days 14 and 28. Challenge
was given at day 45 and necropsies were performed at day 52. In Trial 2, the animals were
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vaccinated by intramuscular injection with the DNA vaccine, followed by electroporation at day
0 and boosted the same way at days 14 and 28. Challenge was given at day 43 and necropsies
performed at day 50. In both trials, challenge was both via intranasal and intramuscular routes
with 106 TCID50/animal of VR2332. Blood was collected at days 0, 7, 14, 17, 21, 28, 40, at the
challenge day, and 5 and 7 days post-challenge. At the end of the experiment, the pigs were
euthanized and the lungs evaluated macroscopically, weighed, and bronchoalveolar lavages
(BAL) performed. The vaccination/challenge trial design is shown as Scheme 2.2. Tissue
samples were collected from each lung lobe, tracheobronchial lymph nodes (TBLN), spleen, and
inguinal lymph nodes (ILN) and then fixed in 10% neutral buffered formalin or kept frozen.
Fixed tissues were sectioned, and stained with hematoxylin and eosin for histologic evaluation.
Lung lesion scores were determined as previously reported (47). All the animal work was done
under a protocol approved by the University of Connecticut Institutional Animal Care and Use
Committee.

2.5. Lymphocyte Proliferation Test: MTT Assay

Peripheral blood mononuclear cells (PBMCs) were isolated from blood using
Histopaque-1077 (Sigma, St. Louis, MO). PBMCs were suspended to 1x107 /mL in RPMI
medium containing 10% FBS, 2 mM L-glutamine, 50 µM -mercaptoethanol, 200 U/mL
penicillin, and 200 µg/mL streptomycin, then seeded in 96-well flat-bottom plates (100 µL/well)
in triplicate. PBMCs were stimulated with VR2332 (10 µg/mL) or media alone. Concanavalin
A (ConA) (10 µg/mL) was used as a positive control. After incubation for 48 h at 37°C in a 5%
CO2 atmosphere, the proliferation responses were detected by a standard MTT (3-(4,5dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide) method. Lymphocyte proliferation was
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expressed as stimulation index (SI), from the ratio of OD570 nm of stimulated compared to that of
unstimulated cells.

2.6. Cytokine Recall Immune Response to PRRSV

PBMCs seeded in 24-well flat-bottom plates (400 µL/well) in duplicate were stimulated
with 200 TCID50 VR2332/well or media alone for 48 h at 37°C in a 5% CO2 atmosphere. The
cells were collected and total RNA was extracted for quantitative real-time PCR analysis.

2.7. Indirect Enzyme-Linked Immunosorbent Assay

For iELISA, purified VR2332 was coated onto 96-well plates at a concentration of 2.5
µg/mL overnight at 4°C, and blocked with 10% dry milk in PBS-T (PBS containing 0.05%
Tween-20) for 2 h at room temperature. The plates were washed with PBS-T and sera diluted 40fold in PBS-T buffer containing 5% dry milk was added. After 60 min at room temperature, the
plates were washed five times with PBS-T buffer and incubated with mouse HRP anti-pig IgG,
(The Jackson Laboratory, Bar Harbor, ME) for 60 min at room temperature. The plates were
washed five times in PBS-T, substrate was added and incubated in the dark at room temperature
for 15 min. The reactions were stopped with 1 M HCl. The plates were read at OD450 in a
microplate reader (Biotek HTK model, Winooski, VT). Archival PRRSV positive and negative
sera of pigs were used as controls in each ELISA run.

2.8. Serum Neutralization
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Test sera were mixed with equal volumes of DMEM containing 100 TCID50 of VR2332
(final serum dilution 1:4). After incubation at 37°C for 1 h, the serum-virus mixtures were added
to MARC-145 monolayers in 96-well plates, and incubated at 37°C in a 5% CO2 atmosphere for
48 h. VR2332 virus plus negative serum and uninfected cells were used as virus and cell
controls, respectively. Neutralization was quantified both by a fluorescence intensity reduction
(FIR) test and qRT-PCR 48 h after infection. For FIR, cells 48 h after infection were washed
three times with PBS and then fixed with 80% cold acetone for 15 min at 4°C. The cells were
reacted with a protein-A purified PRRSV-positive swine serum for 1 h. After three washes with
PBS, FITC-conjugated rabbit anti-pig IgG (Sigma, St. Louis, MO) was incubated for 1 h. After
washing, fluorescence intensity was measured in a microplate reader (Biotek HTK model,
Winooski, VT).

2.9. Quantitative Real-time PCR

Total RNA was extracted from 250 µL of serum or supernatants using TRIzol LS
Reagent or from tissues using TRIzol Reagent (Invitrogen, Grand Island, NY). RNA was
quantified using a spectrophotometer NanoDrop 1000 (Thermo Scientific). cDNA was
synthesized using random primers (Invitrogen, Grand Island, NY) in a 20 µL reaction mixture.
The reaction was run in a thermocycler (Applied Biosystems GeneAmp PCR System 2400) as
follows: 26°C for 10 min, 42°C for 45 min and 75°C for 10 min. SYBR Green real-time PCR
was then performed, using the cDNA as a template and 5’-ATG ATG RCC TGG CAT TCT3’and 5’-ACA CGG TCG CCC TAA TTG- 3’ as the forward and reverse primers for ORF7,
respectively. The PCR reaction was performed at 95°C for 2 min, followed by 40 cycles of 95°C
for 15 s and 61°C for 1 min using the ABI 7500 detection system. For each assay, a standard
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curve was generated using serially diluted RNA which contained 102–107 copies/μL. In each run,
positive and negative reference samples were run along with the test samples. The viral loads
were determined by plotting the Ct values against the standard curve. Melting curves were
analyzed to verify the specificity of the PCR.
For cytokine evaluation, total RNA was extracted from virus-stimulated or media-treated
PBMCs using TRIzol Reagent. cDNA synthesis and real-time PCR followed the same protocol
described above. GAPDH (forward primer: 5’-CGT CCC TGA GAC ACG ATG GT- 3’and
reverse primer: 5’-CCC GAT GCG GCC AAA T -3’) was used as internal control to calculate
the changes of interferon-γ (IFN-γ) (forward primer: 5’-TGG TAG CTC TGG GAA ACT GAA
TG - 3’and reverse primer: 5’- GGC TTT GCG CTG GAT CTG -3’), or Interleukin-10 (IL-10)
(forward primer: 5’- TGA GAA CAG CTG CAT CCA CTT C- 3’and reverse primer: 5’-TCT
GGT CCT TCG TTT GAA AGA AA -3’) by the delta-delta method (48).

2.10.

Lung Lesion Scoring

Lung lesion scoring was done by a board certified veterinary pathologist, blinded to the
treatment groups as previously described (47).

2.11.

Statistical Analysis

Student t-test or Two-way ANOVA was used to evaluate the differences between the
samples within or between groups. The Pearson product-moment correlation coefficient was
calculated. The data were analyzed using GraphPad Prism (version 5.0).
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3. Results

3.1. Characterization of Mosaic T-cell Epitope Vaccines
3.1.1. GP5 Mosaic Vaccine Increased Epitope Coverage Over VR2332

The amino acid sequences of Mosaic 1 and 2 were 88 % identical; while those of Mosaic
1 and VR2332 GP5 and Mosaic 2 and VR2332 GP5 were 93 % and 90.5 % identical,
respectively (Fig. 2.1A). Homologies between GP5-Mosaic sequences with VR2332, NADC9,
NADC30, SDSU73 and MN184(C) are shown in Table 2.1. Mosaic 2, has an average amino acid
sequence identity of 90.25%, which is better coverage than both Mosaic 1 (average identity of
85.75%) or VR2332 (average identity of 86.25%) towards the other 4 strains examined. Mosaics
were optimized for greatest coverage of 9-mer epitope over the peptide set. Two mosaic
sequences increased both positional coverage compared to one mosaic sequence, as shown by
more yellow-colored squares and fewer black-colored ones (Fig. 2.1B), and a better epitope
coverage (66.4% vs 53.4% in exact match, 88.8% vs 82.4% in off-by-1 and 96.5% vs 93.6% in
off-by-2) (Fig. 2.1C).

3.1.2. GP5-Mosaic Vaccine Expression Was Confirmed in vitro

The expression of GP5-Mosaic vaccines 1 and 2 in vitro was confirmed in Escherichia
coli by western blot (Fig. 2.1D). The western blot showed specific protein bands with
approximate molecular weight of 20 kDa consistent with GP5, whereas no bands were detected
with negative control serum (data not shown).

3.2. GP5-Mosaic Vaccine Activated Cellular Responses
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Mosaic vaccination activated lymphocyte proliferative responses as detected 12 days after
the second boost in Trial 1 and 10 days after the second boost in pigs in Trial 2. In Trial 1,
significantly higher (p<0.05) levels of proliferation were detected in PBMCs from both GP5VR2332 (GP5-WT), and GP5-Mosaic vaccinated animals, as compared with vector-control
animals (Fig. 2.2A). In Trial 2, similar results were observed. Virus stimulation induced
significantly higher lymphocyte proliferative responses in GP5-Mosaic-vaccinated animals
compared to vector-control and electroporation-control animals (Fig. 2.2B).
IFN-γ and IL-10 relative fold-changes are shown in Fig. 2.2C and 2.2D, respectively.
Higher IFN-γ mRNA expression was detected in GP5-Mosaic-vaccinated pigs 5 days after
challenge compared to those in electroporation-control (p<0.05) or vector-control pigs (p=0.054)
(Fig. 2.2C). In contrast, significantly lower IL-10 mRNA expression was observed in GP5Mosaic-vaccinated pigs than in electroporation-control pigs at the same time point (p<0.05) (Fig.
2.2D).

3.3. GP5-Mosaic Vaccine Induced Virus-specific Antibodies

GP5-Mosaic vaccines delivered by electroporation in Trial 2, induced significantly higher
levels of antibodies, as detected in sera collected at the challenge day and 5 days after challenge,
than those of control animals (p<0.05) while gene gun in Trial 1 did not (Figs. 2.3A and 2.3B).
In Trial 2, sera collected at the same time points from GP5-Mosaic-vaccinated animals
neutralized virus (Figs. 2.3C and 2.3D), demonstrating that the neutralizing epitope remained
functional. The levels of neutralizing antibodies in sera from GP5-Mosaic-vaccinated pigs were
higher (p<0.01) compared to those in sera from control animals (Fig. 2.3C). The viral copy
numbers were significantly lower (p<0.05) when virus was mixed with sera from GP5-Mosaic-
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vaccinated animals than with sera from control pigs (Fig. 2.3D). The Pearson product-moment
correlation coefficient of these two assays for the full range was 0.69 (Fig. 2.3E).

3.4. Rapid Clearance of Virus in GP5-Mosaic-vaccinated Animals

In Trial 2, viral loads in the GP5-Mosaic-vaccinated group were higher than those in
vector-control or electroporation-control groups 5 days after challenge. However, viral loads in
all GP5-Mosaic-vaccinated animals were reduced by more than 260-fold two days later. In
contrast, the mean viral loads increased 1.2 to 5-fold in vector-control or electroporation-control
groups, respectively (Fig. 2.4A). There were no significant differences in viral loads in lungs or
TBLNs between groups in Trial 2 (Fig. 2.4B). However, viral loads in ILNs and spleens of GP5Mosaic-vaccinated animals were lower than those in control animals (p<0.05 * and p<0.01 **).
In Trial 2, viral loads in sera at necropsy were significantly lower (p< 0.05) in GP5-Mosaicvaccinated pigs than those in Trial 1 (Fig. 2.6).

3.5. Lower Lung Lesion Scores Detected in GP5-Mosaic-vaccinated Animals

Lung lesion scores were significantly lower (p<0.05) in GP5-Mosaic-vaccinated animals
in Trial 2 than those in vector-control animals when evaluated with either 7 or 9 sections of lung
(Fig. 2.4C). No differences were observed in Trial 1 (data not shown).

3.6. Higher Average Daily Weight Gain (ADWG) Recorded in GP5-Mosaic-vaccinated
Animals
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ADWG were 1.44, 0.78 and 0.61 in GP5-Mosaic, vector-control and EP-control groups
respectively in Trial 2 as shown in Fig 2.5. ADWG in GP5-Mosaic group was higher (p=0.056)
than those in EP-control group.

4. Discussion
The high genetic and antigenic variability of PRRSV prevents current vaccines from
conferring broad protection. To address this challenge, several strategies including consensus
sequence vaccines, multisubunit vaccines, molecular breeding by DNA shuffling, mosaic T-cell
epitope vaccines are being investigated (26)(31)(32)(33)(34)(35) (36)(37)(38)(39)(40)(41)(42)
(43)(44)(45)(46). The similarities between HIV and PRRSV in terms of genetic variability made
the mosaic T-cell vaccine an attractive and logical alternative to address such diversity for the
latter. Mosaic vaccines for HIV-1 have been shown to be capable of broadening epitope
recognition and increasing responses to high-frequency epitopic variants (44)(45). Mosaic T-cell
vaccines were pursued in the present study for PRRS.
Two PRRSV GP5-Mosaics developed in this study were aligned with divergent strains.
GP5-Mosaic 2 showed higher sequence homology with those strains than VR2332 which is the
parental strain of a number of commercial MLV vaccines (Table 2.1). When GP5-Mosaic
sequences were compared to previously reported GP5 T-cell epitopes 117LAALICFVIRLAKNC
and 149KGRLYRWRSPVIVEK in both genotypes [17](18), we found the corresponding T-cell
epitopes 117LAALTCFVIRFAKNC and 149KGRLYRWRSPVIIEK in GP5-Mosaic 1 and
117

LAALICFVIRLAKNC and 149KGKLYRWRSPVIIEK in GP5-Mosaic 2. In GP5-Mosaic 1,

there were T121I and F127L substitutions in the first epitope and I161V in the second epitope. In
GP5-Mosaic 2, the first epitope had a perfect match with the reference epitope and there were
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K151R and I161V substitutions in the second epitope. The effect of substitutions such as T121I,
F127L and K151R is likely minimal since mosaic vaccines were used as a pool. Moreover,
I161V substitution may not cause a significant difference because of the highly similar structures
between them.
The lymphocyte proliferation, a general assessment tool for cellular responses
(22)(24)(49)(50)(24)(51), indicated that GP5-Mosaic vaccines elicited such responses, regardless
of the delivery method. Moreover, cytokine profiling, is helpful to evaluate the overall cellular
response. In PRRS, prolonged viremia correlates with a weak innate antiviral response (52)(53),
high levels of IL-10 and TGF (54), low levels of IFN-γ (55) coupled to sub-optimal adaptive
immunity (16). A study also showed that the levels of IFN-γ and IL-10 were good markers of
polarization of the adaptive response, and the level of IL-10 correlated directly with the level of
infected macrophages (56). Therefore, determining IFN-γ and IL-10 levels is useful to evaluate
vaccine performance. Finding that IFN-γ mRNA levels of PRRSV stimulated PBMCs were
significantly increased on 5 DPC, indicated that the GP5-Mosaic vaccine-induced cellular
responses which may be relevant to protection (57)(58)(59). The higher levels of IL-10 mRNA
detected in control pigs suggested that inhibition of adaptive responses could be responsible for
the slower PRRSV clearance in these animals. The observation that levels of IFN-γ and IL-10
tended to be opposite in animals of the same group agreed with a previous study (60).
Detecting neutralizing antibodies in GP5-Mosaic-vaccinated animals indicated the
preservation of a relevant B-cell epitope (15)(16) in a T-cell mosaic vaccine background. This is
also reflected, by sequence data, that Mosaic1 has a single mutation (L39F) within the
neutralizing epitope while Mosaic 2 has none. The effect of the L39F mutation on Mosaic 1 on
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neutralization was not specifically tested as the two mosaics were mixed to vaccinate, and
Mosaic 2 may have compensated potential deficits of Mosaic 1.
The rapid virus clearance in sera at necropsy in GP5-Mosaic-vaccinated pigs in Trial 2
but not in Trial 1, together with the fact that further evidence showed that viral copy numbers in
serum of GP5-Mosaic vaccinated pigs at 7DPC in Trial 2 were significantly lower than those of
GP5-Mosaic vaccinated pigs in Trial 1 (Fig 2.6), suggested that electroporation was more
effective than gene gun delivery. Electroporation utilizes a short high-voltage pulse to increase
DNA uptake and transfection efficiency (61)(62)(63). In Trial 2, viral loads were lower in ILNs
and spleens of GP5-Mosaic-vaccinated animals than those in control animals (p<0.05) but not in
lungs or TBLNs. There were no significant differences in viral loads in PAMs or BAL fluid
among groups. A possible explanation is that there were much higher viral loads in lungs upon
challenge (64) and since necropsy was performed 7 days after challenge, there was likely not
enough time to allow the host to clear the virus in local tissues (65)(66). It is possible that
systemic responses seen in GP5-Mosaic-vaccinated animals cleared circulating virus more
effectively and reduced the loads in ILNs and spleen.
The lower lung lesion scores and the higher ADWG in GP5-Mosaic-vaccinated animals
in Trial 2 are further evidence that a level of protection was achieved. Testing protection against
divergent PRRSV strains will further determine the value of the GP5-Mosaic vaccine to control
PRRS.
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Table 2.1 GP5-Mosaic Sequencea Homologies to Selected Genotype II PRRSV Strains
Mosaic 1 Mosaic 2 VR2332 NADC9 NADC30 SDSU73
Mosaic 1
100
88
93
88
85
85
Mosaic 2
88
100
90.5
90
91
90
VR2332
93
90.5
100
89
84
87
NADC9
88
90
89
100
85
85
NADC30
85
91
84
85
100
86
SDSU73
85
90
87
85
86
100
MN184C
85
90
85
87
93
84
a
PRRSV GP5 sequences were compared using BLAST (NCBI, Bethesda, MD)
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MN184C
85
90
85
87
93
84
100

Scheme 2.1. Construct of GP5-Mosaic vaccine. The mosaic sequences were separately inserted
into pHCMV1 Title this diagram Mosaic DNA Vaccine Construction (courtesy of Caitlin
O’Connell)
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Table 2.2 GP5-Mosaic Vaccinea Immunogenicity Testing in Pigs
Gene gunb (Trial 1)

Electroporationc (Trial 2)

Experimental Group

Vaccine Dose

Experimental Group

Vaccine Dose

Negative control
(n=3)

100 µg empty
phCMV1

Negative control
(n=3)

Electroporation
PBS buffer

GP5 control
(n=3)

100 µg VR2332
phCMVORF5

Vector control
(n=3)

1 mg empty phCMV1

Mosaic pool
(n=4)

100 µg mosaic
plasmid cocktail

Mosaic pool
(n=4)

1 mg mosaic plasmid
cocktail

a

The GP5-Mosaic DNA vaccines were given as a cocktail
The vaccines were delivered by Helios Gene Gun (Bio-Rad Hercules, CA) in the inner aspect of
the thigh at 600 psi
c
Vaccines were injected in the semimembranous muscle with a 1-1 ½”, 21 gauge needles
followed by electroporation with 0.5 A pulse width 52 milliseconds with second interval between
pulses (3 pulses/pig) using Cellectra Electroporation Unit (Inovio Pharmaceuticals Inc. Blue
Bell, PA)
b
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st

0

nd

1 boost

Vaccination

7

14

2 boost

21

28

Challenge

40 45

Necropsy

4dpc 7dpc

Blood
collection

Scheme 2.2. Vaccination/Challenge Design for Trial 1&2. Blue arrows indicate the major
operations including vaccination, boost, challenge, and necropsy. Red arrows indicate blood
sample collections.
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A

Asterisk (*) indicates a single, fully conserved residue. Colon (:) indicates strongly similar properties. Period (.)
indicates weakly similar properties (Gonnet PAM 250 matrix).

Coverage
( mean per sequence)

B
C
1.0

off by 2
off by 1
exact match

0.8
0.6
0.4
0.2
0.0

1 mosaic

2 mosaics

Figure 2.1 Characterization of GP5-Mosaic Sequences. A. GP5-Mosaic sequences aligned
with VR2332 GP5 (GP5-WT). Mosaic1: Mosaic2 = 88% identical; Mosaic1: GP5-WT = 93%
identical; Mosaic2: GP5-WT = 90.5% identical. B. Positional coverage over the 748 Genotype II
sequences as obtained by the Mosaic Posicover Tool (Los Alamos National Laboratory). Each
colored square represents an amino acid, each row is a sequence, and each column is an
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alignment position. Each amino acid is colored according to the set of 9 amino acid strings that
contain it: if all 9-mers that overlap with amino acids are perfectly matched in a peptide set, the
amino acid is colored yellow; increasingly red values indicate fewer matches, and black indicates
no matches. C. Comparison of one mosaic sequence and two mosaic sequences in epitope
coverage over the 748 Genotype II sequences as obtained by the Mosaic Epicover Tool.
Coverage denotes the proportion of 9-mers in each of the 748 PRRSV GP5 sequences that are
present in that antigen set, averaged over the 748 sequences. ‘Off-by-2’ indicates coverage of 9mers that match at 7 of 9 positions, and ‘off-by-1’ indicates coverage of 9-mers that match at 8
of 9 positions. D. E. coli BL21 cells used to test expression of GP5-Mosaic proteins. Lane 1 and
2 represent GP5-Mosaic protein 1 and 2.
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A
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p=0.054
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2

EP-Ctl
Vector-Ctl
GP5-Mosaic

Medium
ConA
VR2332

D

*

4
0
-4
-8

GP5-Mosaic

6

8

Vector-Ctl

ConA

VR2332

Medium

ConA

VR2332

Medium

VR2332

C

*

*

1

0

IL-10 Fold Change

8

EP-Ctl

IFN Fold Change

ConA

1

*

2

Medium
ConA
VR2332

*

EP-Ctl

Vector-Ctl
GP5-WT
GP5-Mosaic

Medium
ConA
VR2332

*

2

0

*

3

Stimulation Index

*

Medium

Stimulation Index

3

Figure 2.2 Vaccine-Induced Cellular Responses. A. Proliferative responses in PBMCs
collected at day 38 detected by the MTT method after 48h of antigen stimulation in Trial 1. B.
Proliferative responses in PBMCs collected at day 40 detected by the MTT method after 48h of
antigen stimulation in Trial 2. C. IFN-γ mRNA fold changes of PBMCs at 5 days after challenge
in Trial 2. D. IL-10 mRNA fold changes of PBMCs at 5 days after challenge in Trial 2. Each bar
represents the mean value of each group. Variation expressed as standard error of the mean.
Three experiments were performed independently. Significant difference is calculated using a
repeated measure analysis (p<0.05*). (EP: electroporation)
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Figure 2.3 Vaccine-Induced Antibody Responses. A. Virus-specific antibodies detected by iELISA

in Trial 1. B. Virus-specific antibodies detected by iELISA in Trial 2. C. Detection of
neutralizing antibodies by FIR. D. Changes in viral copy numbers induced by serum antibodies
detected in infected cell supernatants by qRT-PCR. E. Pearson correlation between C&D. Each
bar represents the mean value of each group. Variation expressed as standard error of the mean.
Three experiments were performed independently. Significant differences calculated by a Twoway ANOVA or student t test (p<0.05*, p<0.01** or p<0.001***) (DPC: days post challenge;
DPSB: days post second boost; EP: electroporation; FIR: fluorescence intensity reduction).
56

5 D.P.C
7 D.P.C

A
1000

269X
5X

100

1000
100

*

*

LUNG
TBLN
ILN
SPLEEN

**

10

EP-Ctl
Vector-Ctl
GP5-Mosaic

EP-Ctl
Vector-Ctl
GP5-Mosaic

0.1

EP-Ctl
Vector-Ctl
GP5-Mosaic

1
EP-Ctl
Vector-Ctl
GP5-Mosaic

Viral copy numbers
/ng total RNA

10000

GP5-Mosaic

Vector-Ctl

B

EP-Ctl

EP-Ctl

1

GP5-Mosaic

10

Vector-Ctl

Viral copy numbers
/ng total RNA

1.2X

C
a

b

*

*

2

GP5-Mosaic

Vector-Ctl

EP-Ctl

GP5-Mosaic

0

Vector-Ctl

1

EP-Ctl

Lesion score

3

Figure 2.4 Virus Clearance and Lung Lesion Scores in Trial 2. A. Comparison of viral copy

numbers in serum between 5 DPC and 7 DPC. B. Viral copy numbers in tissues at necropsy (7
DPC). C. Lung lesion scores. Scores were significantly lower (p<0.05) in GP5-Mosaicvaccinated animals than those in vector-control animals. (a: score based on 7 lung sections or b:
9 lung sections;). (DPC: days post challenge; EP: electroporation).
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Figure 2.5 Average Daily Weight Gain (ADWG) within 14DPC in Trial 2. Each bar
represents the mean value of each group. Variation expressed as standard error of the mean.
(DPC: days post challenge; EP: electroporation).
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Figure 2.6 Comparison of Virus Clearance in Serum in Trial 1&2. Comparison of viral copy
numbers in serum between Trial 1&2 at 7 DPC. Left panel showed viral copy numbers in Trial 1
and right panel showed viral copy numbers in Trial 2. Each bar represents the mean value of
each group. Variation expressed as standard error of the mean. Three experiments were
performed independently. Significant differences calculated by student t test (p<0.05*) (DPC:
days post challenge; EP: electroporation;).
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Chapter III GP5-Mosaic T-cell Vaccine Induces Broad Reactivity ex-vivo to Heterologous
Type II PRRSV Strains and Confers Partial Protection in Pigs

Summary
A previous study showed that GP5-Mosaic T-cell vaccine, formulated in our laboratory as DNA
vaccines, was immunogenic and induced partial protection in vaccinated pigs. In the present
study, a vaccination/challenge trial was performed in pigs to test further whether the GP5-Mosaic
vaccine had the capacity to induce cross-reactive cellular responses in swine. The GP5-Mosaic
DNA vaccines complexed to cationic liposomes were administered to experimental pigs by
intramuscular injection followed by three boosters at days 14, 28 and 42. Periodic sampling of
blood and testing of vaccine-induced responses followed. Significantly higher levels of
interferon-γ (IFN-γ) mRNA expression were detected in virus-stimulated peripheral blood
mononuclear cells (PBMCs) of GP5-Mosaic-vaccinated pigs as compared to those detected in
control pigs vaccinated with either GP5 wild type (GP5-WT) or empty vector at 21, 35 and 48
days after vaccination (p<0.05). Moreover, significantly higher levels of IFN-γ mRNA were
detected in PBMCs from GP5-Mosaic-vaccinated pigs stimulated by four Genotype II PRRSV
strains including VR2332, NADC9, NADC30 and SDSU73 which have at least 10% difference
in GP5 amino acid sequence between them, while such responses were recorded only upon
VR2332 stimulation in GP5-WT-vaccinated pigs. In addition, the levels of virus-specific
antibodies were higher in GP5-Mosaic-vaccinated pigs than in control pigs. These antibodies
were neutralizing. The experimental pigs that received the GP5-Mosaic vaccine were partially
protected from challenge with VR2332 as indicated by significantly lower viral loads in sera,
tissues and lower lung lesion scores (p<0.05). The data demonstrates that GP5-Mosaic vaccine
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induced cross-reactive cellular responses to diverse strains, higher levels of neutralizing
antibodies, and protection in pigs.

Key words: PRRS, PRRSV, mosaic T-cell vaccine, broad immune responses

1. Introduction
Porcine reproductive and respiratory syndrome (PRRS) is the most important infectious
disease affecting swine worldwide. PRRS is characterized by reproductive failure and
respiratory disease (1)(2). PRRS causes a major negative economic impact to all major pork
producing countries. For instance, the annual losses are more than 660 million dollars in the
United States alone (3). The causative pathogen, PRRSV, is a positive-sense, single-stranded
RNA virus with an enveloped virion and is classified as a member of the genus Arterivirus,
family Arteriviridae, order Nidovirales (4)(5). The viral genome is approximately 15 kb, and
encodes 8 structural proteins and 14 non-structural proteins (6)(7)(8)(9). The main feature of
PRRSV is its great genetic and antigenic diversity. There are two main genotypes, Genotype I
(European type) and Genotype II (North American type) (10), with up to 40% difference
documented in the whole genome between them, and up to 20% divergence within the same
genotype having been recorded (11).
The control of PRRS relies largely on vaccination with modified-live vaccines and killedvirus vaccines in the field. Additionally, autogenous vaccines are used (12). Unfortunately,
vaccines used at present only confer protection against homologous strains and possess weak or
no ability to provide cross-protection to heterologous strains which are circulating in the field
and constantly mutating. Therefore, this high genetic and antigenic diversity is the major
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obstacle for the control of PRRS. To address this diversity challenge, vaccines that can provide
cross-protection are in urgent demand. Thus, the development of new vaccines is being
intensively studied. There are several different approaches being attempted including consensus
sequence vaccines (13)(14)(15), multi-subunit vaccines (16)(17)(18)(19), molecular breeding by
DNA shuffling (20)(21)(22)(23) and mosaic T-cell epitope vaccines (24)(25)(26)(27)(28)
(29)(30). These approaches are aimed at providing expanded vaccine breadth and depth of
antigen for highly variable viruses. In our previous study, we have shown that a GP5-Mosaic
vaccine designed using the Mosaic Vaccine Tool Suite originally developed for HIV at Los
Alamos National Laboratory (Los Alamos, NM) (24) was immunogenic and conferred partial
protection in pigs when delivered as a DNA vaccine (30).
To further characterize the vaccine performance in terms of breadth and depth of
responses, we sought to enhance the immune response induced by our vaccine. Recent studies
have shown that delivery of DNA vaccines in liposomes resulted in improved DNA uptake
efficiency and higher levels of antigen expression in different animal models which range from
mouse to non-human primate (31)(32)(33). Therefore, liposomes are a very attractive delivery
system to improve our DNA vaccine efficiency. In this study, the GP5-Mosaic vaccine was
complexed to cationic liposomes for delivery into pigs. The ability of the vaccine thus
formulated to induce broad cross-reactive cellular responses was tested ex-vivo using four
Genotype II PRRSV strains diverging with one another in amino acid sequence by at least 10%.
The results of vaccine-induced responses and protection are discussed.

2. Materials and Methods

2.1. Viruses and Cells
62

NADC9, NADC30, SDSU73 were kindly provided by Drs. Kay Faaberg and Kelly Lager
at USDA ARS. Viruses were propagated in MARC-145 cells. The cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U penicillin/mL, and 100 µg streptomycin/mL. The virus titers
were calculated using the Reed and Muench method (34). The viruses were purified over
continuous cesium chloride gradients, quantified using a spectrophotometer NanoDrop 1000
(Thermo Scientific) and stored at -80°C for future use. Purified VR2332 was used as antigen for
indirect ELISA. Titrated viruses were used for neutralization assay, recall immune response
assay and challenge.

2.2. Protein Sequence Alignment and Phylogenetic Analysis
The protein sequence alignments between GP5 sequences of VR2332, NADC9,
NADC30, SDSU73, Mosaic 1 and Mosaic 2 and phylogenetic tree were evaluated using MEGA
7 (Molecular Evolutionary Genetics Analysis) (www.megasoftware.net).

2.3. Preparation of Liposomes and Formulation with Vaccine DNA
Liposomes were prepared by the thin-film hydration method (35). Briefly, 1,2-dioleoylsn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-racglycerol) (DPPG) and Cholesterol (8:1:1 molar ratio) (Avanti Polar Lipids, Inc. Alabaster, AL)
were mixed and dissolved in chloroform (Fisher Scientific Pittsburgh, PA). The lipid/chloroform
solution was evaporated using a Buchi Rotavapor followed by being placed under vacuum for 12
hours. Phosphate Buffer (pH 6.5), made isotonic with RNase-free Sucrose (MP Biomedicals),
was then added to the dry lipid film. The lipid film was hydrated with the buffer at <10 degrees
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Celsius with intermittent sonication (10-20 second durations) until all of the lipid was dissolved.
The liposomes were then subjected to two freeze-thaw cycles (i.e. liquid nitrogen for 5 minutes
followed by 55°C for 10 minutes). Lastly, the liposomes were extruded using a LIPEX™
extruder (Northern Lipids Inc., Canada) eight times through a 200-nm polycarbonate membrane
(Whatman® Nuclepore Track-Etched Membranes) and one time through a stacked 150 nm and
50 nm polycarbonate membranes at 250 psi. Chitosan oligosaccharide solution (50 µM, MW 5k)
was slowly added to the liposomal dispersion (250 µM) to form a diluted dispersion of liposomes
coated with chitosan. The coated liposomes were then slowly mixed with pDNA (54 µg/mL) to
form a liposome-pDNA complex. The complexes were then concentrated using a Vivaflow 50R
crossflow filter (Sartorius). The final concentrations were 1 mM total lipid, 100 µM chitosan and
0.54 mg/mL pDNA. The particle size and zeta-potential were measured for each stage of the
coating process using a Malvern Zetasizer.
The particle size and zeta-potential of the liposomes and liposome/pDNA complex were
conducted using a Malvern Zetasizer Nano ZS90. The liposomal dispersions were diluted
approximately 50 times prior to the measurement. All measurements were conducted at 25 °C in
triplicate and were reported as mean ± StDev (Z-Ave ± distribution width for particle size) and
mean ± StDev (zeta-potential ± mean of zeta-deviation).

2.4. Vaccination and Collection of Samples
Three to four-week-old, PRRSV-free, porcine circovirus-2-free, cross-bred piglets were
used in this study. The GP5-Mosaic vaccines were delivered as liposome/pDNA complexes.
Briefly, the liposome/DNA-GP5-Mosaic vaccine complexes containing 500 µg of DNA was
injected intradermally (0.1 mL) on the back of ear and intramuscularly (0.9 mL) on the neck
musculature at day 0 and boosts were given at days 14, 28 and 42. Virus challenge was given at
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day 48 and necropsies were performed at day 62. Challenge was both via intranasal and
intramuscular routes with a total of 106 TCID50/pig of VR2332. Blood samples were collected at
days 0, 7, 14, 21, 28, 35, 42, the challenge day, and 4, 7, 11 and 14 days post-challenge (shown
in Scheme 3.2). At the end of the experiment, the pigs were euthanized and the lungs evaluated
macroscopically, weighed, and bronchoalveolar lavages (BAL) performed. Tissue samples were
collected from each lung lobe, tracheobronchial lymph nodes (TBLN), spleen, and inguinal
lymph nodes (ILN) and then fixed in 10% neutral buffered formalin or kept frozen. Fixed tissues
were sectioned, and stained with hematoxylin and eosin for histologic evaluation. Lung lesion
scores were evaluated as previously reported (36). All the animal work was done under a
protocol approved by the University of Connecticut Institutional Animal Care and Use
Committee.

2.5. Recall Cellular Response to PRRSV
PBMCs collected at days 21, 28 and 35 seeded in 24-well flat-bottom plates (5x105
cells/well) in duplicate were stimulated with 200 TCID50 VR2332/well or mock for 48 h at 37°C
in a 5% CO2 atmosphere. The cells were collected and total RNA was extracted for quantitative
real-time PCR analysis. The same test was also done with PBMCs collected at days 0 and at
challenge day. The cells were stimulated with 200 TCID50 of VR2332, NADC9, NADC30 or
SDSU73 /well or mock stimulated for 48 h at 37°C in a 5% CO2 atmosphere.

2.6. Indirect Enzyme-Linked Immunosorbent Assay
ELISA was performed as described previously (30). Briefly, CsCl2 purified VR2332 was
coated onto 96-well plates at a concentration of 2.5 µg/mL overnight at 4°C, and the plates were
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blocked with 10% dry milk in PBS-T (PBS containing 0.05% Tween-20) for 2 h at room
temperature. The plates were washed twice with PBS-T and serum samples diluted 40-fold in
PBS-T buffer containing 5% dry milk were added. After 60 min at room temperature, the plates
were washed five times with PBS-T buffer and incubated with mouse HRP anti-pig IgG (The
Jackson Laboratory, Bar Harbor, ME) for 60 min at room temperature. The plates were washed
five times in PBS-T, substrate was added and incubated in the dark at room temperature for 15
min. The reactions were stopped with 1 M HCl solution. The plates were read at OD450 in a
microplate reader (Biotek HTK model, Winooski, VT). Archival PRRSV positive and negative
sera of pigs were used as controls in each run.

2.7. Serum Neutralization
Serum neutralization tests were performed using a previously reported method (30).
Briefly, test sera were mixed with equal volumes of DMEM containing 100 TCID50 of VR2332
(final serum dilution 1:4). After incubation at 37°C for 1 h, the sera-virus mixtures were added to
MARC-145 monolayers in 96-well plates and incubated at 37°C in a 5% CO2 atmosphere for 48
h. VR2332 virus plus negative serum and uninfected cells were used as virus and cell controls,
respectively. Neutralization was quantified both by a fluorescence intensity reduction (FIR) test
and qRT-PCR 48 h after infection. For FIR, cells 48 h after infection were washed three times
with PBS and then fixed with 80% cold acetone for 15 min at 4°C. The cells were reacted with a
protein-A purified PRRSV-positive swine serum for 1 h. After three washes with PBS, FITCconjugated rabbit anti-pig IgG (Sigma, St. Louis, MO) was incubated for 1 h. After washing,
fluorescence intensity was measured in a microplate reader (Biotek HTK model, Winooski, VT).
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2.8. Quantitative Real-time PCR
Total RNA was extracted from 250 µL of serum or supernatants using TRIzol LS
Reagent or from tissues using TRIzol Reagent (Invitrogen, Grand Island, NY). RNA was
quantified using a spectrophotometer NanoDrop 1000 (Thermo Scientific). cDNA was
synthesized using random primers (Invitrogen, Grand Island, NY) in a 20 µL reaction mixture.
The reaction was run in a thermocycler (Applied Biosystems GeneAmp PCR System 2400) as
follows: 26°C for 10 min, 42°C for 45 min and 75°C for 10 min. SYBR Green real-time PCR
was then performed, SYBR qPCR Master Mix was purchased from Bimake (Bimake, Houston,
TX) and the cDNA used as a template and 5’-ATG ATG RCC TGG CAT TCT- 3’and 5’-ACA
CGG TCG CCC TAA TTG- 3’ as the forward and reverse primers for ORF7, respectively. The
PCR reaction was performed at 95°C for 2 min, followed by 40 cycles of 95°C for 15 s and 61°C
for 1 min using Bio-Rad CFX96 Touch System (Bio-Rad, Hercules, CA). For each assay, a
standard curve was generated using serially diluted RNA which contained 102–107 copies/μL. In
each run, positive and negative reference samples were run along with the test samples. The viral
loads were determined by plotting the Ct values against the standard curve. Melting curves were
analyzed to verify the specificity of the PCR.
To test for cytokine expression, total RNA was extracted from virus-stimulated or mocktreated PBMCs using TRIzol Reagent. cDNA synthesis and real-time PCR followed the same
protocol described above. GAPDH (forward primer: 5’-CGT CCC TGA GAC ACG ATG GT3’and reverse primer: 5’-CCC GAT GCG GCC AAA T -3’) was used as internal control to
calculate the changes of IFN-γ (forward primer: 5’-TGG TAG CTC TGG GAA ACT GAA TG 3’and reverse primer: 5’- GGC TTT GCG CTG GAT CTG -3’) or Interleukin-10 (IL-10)
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(forward primer: 5’- TGA GAA CAG CTG CAT CCA CTT C- 3’and reverse primer: 5’-TCT
GGT CCT TCG TTT GAA AGA AA -3’) by the delta-delta method (37).

2.9. Lung Lesion Scoring
Lung lesion scoring was done by a board certified veterinary pathologist, blinded to the
treatment groups as previously described (36).

2.10.

Statistical Analysis

Student t-test or Two-way ANOVA was used to evaluate the differences between the
samples within or between groups. The data were analyzed using GraphPad Prism (version 7.0).

3. Results
3.1. Sequence Alignment and Analysis of GP5

The GP5 amino acid (aa) sequences of Mosaic 1, Mosaic 2, NADC9, NADC30 and
SDSU73 were of the same size and with no deletions or insertions, when compared to VR2332,
the prototype of genotype II PRRSV strains. Sequence alignments showed that aa identities
ranged from 84-89% (Scheme 3.1). To further investigate the genetic relationship of these
strains, phylogenetic trees were built using neighbor-joining method based on the aa sequences
of the two mosaics and four Type II PRRSV strains. The six sequences could be roughly
categorized into two subgroups (Fig.3.1) with the two far ends being NADC30 and VR2332.
Mosaic 1 and Mosaic 2 were closely related to VR2332 and NADC30, respectively. NADC30
shared high aa identity with Mosaic 2 and VR2332 shared high aa identity with Mosaic 1.
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3.2. Size of Liposome/DNA Complexes Optimum for Processing and Activation of
Cellular Immunity

Particle sizes were characterized, and the distribution was shown to be very narrow. The
size of liposome only was 144.40±1.44 nm, the size of liposome+chitosan was 228.20±4.36 nm,
and the size of liposome/pDNA complex was 380.93±6.66 nm (Table 3.1).

3.3. GP5-Mosaic Vaccine Activated Both Humoral and Cellular Responses
A higher IFN-γ mRNA expression was detected in PBMCs from pigs receiving the GP5Mosaic vaccine collected at days 21, 35 and 48 compared to those detected in vector-control pigs
(p<0.05). Similar differences were also observed between the pigs receiving GP5-WT vaccine
and vector-control pigs. GP5-Mosaic vaccine induced significantly higher levels of antibodies, as
detected in sera collected at days 21 (p<0.05) and 35(p<0.001), (but not at day 14), than those of
vector-control animals (Figure 3.2C). The positive control, GP5-WT vaccine induced
significantly higher levels of antibodies as detected in sera collected at day 35 compared to those
of vector-control animals (p<0.01). The sera collected at challenge day from GP5-Mosaicvaccinated animals neutralized virus (Figs. 3.2B), and the levels were significantly higher
(p<0.01) compared to those in sera from vector-control animals (Fig. 3.2B). As expected, the
ability to induce neutralizing antibodies was also detected in GP5-WT-vaccinated animals.

3.4. GP5-Mosaic Vaccine Induced Broad Cellular Responses ex vivo

69

GP5-Mosaic vaccine induced broad recall cellular responses as detected in vitro by the
significantly higher levels of IFN-γ mRNA relative fold-change detected upon stimulation of
PBMCs of GP5-Mosaic-vaccinated pigs with four divergent Genotype II PRRS virus strains
(VR2332, NADC9, NADC30 and SDSU73) compared to those in mock controls (p<0.05) shown
in Fig.3.3. The response was shown as only significantly higher IFN-γ mRNA expression in
VR2332-stimulated PBMCs in GP5-WT-vaccinated pigs at the same time points compared to
those in mock controls. No such change was detected in those of vector-control pigs.

3.5. Rapid Clearance of Challenge Virus in GP5-Mosaic-vaccinated Pigs

Viral loads of sera in both GP5-WT and GP5-Mosaic-vaccinated pigs were significantly
lower than those in vector-control pigs at 10 and 14 DPC (p<0.05). The GP5-Mosaic vaccine
showed indistinguishable capability of reducing viral loads in serum from the GP5-WT vaccine.
Furthermore, viral loads in sera decreased steadily in approximately 4 logs from 4 to 14 DPC in
both GP5-WT and GP5-Mosaic-vaccinated pigs while viral loads remained about the same level
in the vector-control pigs (Fig.3.4A). Viral loads in tissues including lung, TBLN, spleen and
ILN of both GP5-WT and GP5-Mosaic-vaccinated pigs were significantly lower than those in
vector-control pigs (p<0.01). A significant difference between GP5-Mosaic and GP5-WT group
was undetectable (Fig. 3.4B).

3.6. Lower Lung Lesion Scores Detected in GP5-Mosaic-vaccinated Animals
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Lung lesion scores were significantly lower in GP5-Mosaic-vaccinated animals than
those in vector-control animals when evaluated with either 9 sections of lung (Fig. 3.4C,
p<0.05). No differences were observed between GP5-WT and GP5-Mosaic-vaccinated groups.
4. Discussion
In order to address the extraordinary diversity of PRRSV, GP5-Mosaic vaccines were
developed in our laboratory and their immunogenicity was confirmed (30). The potential of the
GP5-Mosaic vaccines to induce broad cellular responses was further investigated in this study.
Two GP5-Mosaic sequences and four Genotype II PRRSV strains including VR2332, NADC9,
NADC30 and SDSU73 which showed at least 10% difference with one another in GP5 aa
sequences were used to generate a phylogenetic tree using the neighbor-joining method to
establish relationships. Interestingly, GP5-Mosaic 1 was the closest to VR2332 while GP5Mosaic 2 was the closest to NADC30 among all the sequences, which indicated that the two
GP5-Mosaic sequences showed broad coverage spanning strains belonging to different lineages.
This is supported by the fact that VR2332 and NADC30 were used as the two far ends of the
phylogenetic tree with only 84% aa identity between them (Fig.3.1). Therefore, altogether we
could expect that GP5-Mosaic vaccine would induce broader cellular responses than GP5-WT
when PBMCs are stimulated with the strains listed above.
The Mosaic vaccines were delivered using cationic liposome/pDNA complexes. Studies
have shown that immunization with small liposomes (~100 nm) tended to induce a Th2 response,
whereas large liposomes (≥ 400 nm) tended to induce a Th1 response and higher IFN-γ levels
(38). The size of our liposome/pDNA (Liposome/GP5-Mosaic, GP5-WT or vector-control)
particles was characterized to be 380.93±6.66 nm (Table.3.1) which are approximately 400 nm
and thus could be considered large liposomes. Therefore, the responses induced by the
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liposome/pDNA complexes were consistent with Th1 responses with higher levels of IFN-γ,
which reportedly play a significant role in PRRS control (39). Higher levels of IFN-γ mRNA
expression were recorded at days 21, 35, and 48. Vaccination of pigs with the GP5-Mosaic
vaccine also induced humoral responses as shown by a steady increase in antibodies over time,
and higher levels of neutralizing antibodies before challenge. Interestingly, GP5-Mosaic vaccine
induced even higher levels of antibodies than GP5-WT (p<0.001 vs p<0.05 at day 35, p<0.05 vs
no significance at day 21) compared to vector-control pigs. The use of GP5-Mosaic vaccine as a
cocktail of Mosaic 1 and Mosaic 2 may explain, in part, the improvement in vaccine coverage
and the difference in responses.
Mosaic vaccines for HIV-1 have been shown to broaden epitope recognition and increase
responses to high-frequency epitopic variants (27)(28). In the present study, GP5-Mosaic vaccine
induced broader cellular responses compared to GP-WT vaccine, as shown by the significantly
higher levels of IFN-γ mRNA expression in response to four divergent Genotype II strains tested
in recall stimulation of PBMCs. In contrast, PBMCs from GP5-WT-vaccinated pigs only
responded to homologous stimulation with VR2332. No recall responses were detected in the
vector-control pigs. When comparing the conservation of GP5 T-cell epitopes with two reference
ones, we found that GP5-Mosaic 1 had one perfectly matched T-cell epitope with VR2332, while
Mosaic 2 had a perfect match with NADC9 T-cell epitope 1, and Mosaic 2 had a perfect match
with NADC30 and SDSU73 T-cell epitope 2 (Table 3.2). These findings further supported the
fact that GP5-Mosaic vaccine showed a broader T-cell epitope identity with all four Genotype II
PRRSV strains than GP5-WT, which is homologous to VR2332. This could explain the broader
recall immune responses recorded ex vivo with PBMCs from pigs vaccinated with the GP5Mosaic vaccine. Compared with IFN-γ mRNA expression at challenge day in GP5-Mosaic-
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vaccinated pigs, lower levels of IFN-γ mRNA were recorded at 4 DPC. This coincided with
higher levels of IL-10 mRNA expression recorded at that time point which may have exerted
temporary suppressive effects (data not shown). Nevertheless, the data demonstrates that the
GP5-Mosaic vaccine expanded both the depth and breadth of antigen recognition, thus it induced
much broader cellular responses than GP5-WT vaccine ex-vivo. This data supports the potential
of the GP5-Mosaic vaccine in providing cross-protection in pigs. Additionally, investigations to
identify new potential T-cell epitope(s) in GP5-Mosaic sequences need to be considered, as data
of this study suggested their existence.
The rapid virus clearance upon vaccination with either GP5-Mosaic or GP5-WT supports
that complexing pDNA to liposomes was an effective system to deliver DNA vaccines. The
lower lung lesion scores in GP5-Mosaic-vaccinated animals is further evidence that a level of
protection was achieved. Testing protection against divergent PRRSV strains will be essential
and critical to further determine the value of the GP5-Mosaic vaccine to control PRRS.
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Figure 3.1. Phylogenetic Analysis Based on Amino Acid Sequences of GP5 of Two Mosaic
Sequences and 4 Genotype II PRRSV Strains. The analysis was done using neighbor-joining
method of MEGA7.0.
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Scheme 3.1. Selection of Diverse PRRSV Strains. Percentage showing GP5 amino acid
sequences identities between selected strains. Sequences were aligned using BLAST.
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Table 3.1. Particle Size Results

Liposomes
Only
Liposomes+
Chitosan
Liposomes +
Chitosan +
pDNA

Size (d.nm)

StDev

PDI

StDev

Zeta Potential
(mV)

StDev

144.40

1.44

0.15

0.02

-44.53

19.00

228.20

4.36

0.10

0.03

16.67

4.69

380.93

6.66

0.16

0.01

11.80

3.66
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1st boost
Vaccination
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14

2nd boost 3rd boost

21

28

42

Necropsy

Challenge

48

4dpc
7dpc

Blood
collection

10dpc
14dpc

Scheme 3.2. Vaccination/Challenge Design. Blue arrows indicate the major operations
including vaccination, boost, challenge and necropsy. Red arrows indicate blood sample
collections.
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Figure 3.2. Vaccine-induced Humoral and Cellular Responses. A. Virus-specific antibodies
detected by iELISA over time. B. Changes in viral copy numbers induced by serum antibodies
detected in infected cell supernatants by qRT-PCR. C. IFN-γ mRNA fold changes of PBMCs at
days 21, 35 and 48 post immunization. Each bar represents the mean value of each group.
Variation expressed as standard error of the mean. Three experiments were performed
independently. Significant differences calculated by a Two-way ANOVA or student t test
(p<0.05*, p<0.01**, p<0.001*** or p<0.0001****).
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Figure 3.3. GP5-Mosaic Vaccine Induced a Broad Spectrum of Recall Cellular Responses
ex vivo. IFN-γ mRNA fold changes of PBMCs at days 0, challenge and 4DPC in responding to
VR2332, NADC9, NADC30 and SDSU73. Fold increase less than 2 was not considered as real
change. Each bar represents the mean value of each group. Variation expressed as standard error
of the mean. Three experiments were performed independently. Significant differences
calculated by a student t test (p<0.05*).
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Figure 3.4. Virus Clearance and Lung Lesion Scores. A. Comparison of viral copy numbers in
serum from 0 DPC to 14 DPC. B. Viral copy numbers in tissues at necropsy (14 DPC). C. Lung
lesion scores. Scores were significantly lower (p<0.05) in GP5-Mosaic-vaccinated animals than
those in vector-control animals. (DPC: days post challenge).
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Table 3.2. Conservation of PRRSV GP5 B-cell/T-cell epitopes
GP5/PRRSV

B-cell epitope

reference

37SHLQLIY

117LAALICFVIRLAKNC

149KGRLYRWRSPVIVEK

Mosaic 1

37SHFQLIY

117LAALTCFVIRFAKNC

149KGRLYRWRSPVIIEK

Mosaic 2

37SHLQLIY

117LAALICFVIRLAKNC

149KGKLYRWRSPVIIEK

VR2332

37SHLQLIY

117LAALTCFVIRFAKNC

149KGRLYRWRSPVIIEK

NADC9

37SNLQLIY

117LAALICFVIRLAKNC

149KGRLYRWRSPVIVEK

NADC30

37SHLQLIY

117LAALICFAIRLAKNC

149KGKLYRWRSPVIIEK

SDSU73

37SHFQSIY

117LAALICFIIRLAKNC

149KGKLYRWRSPVIIEK

Consensus

* - - * -* *

T-cell epitope 1

* * * *- **-** - -* * *

Reference epitopes cited from studies (66)(65)
*means perfect match, _means substitution
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T-cell epitope 2

* * - * * * * * * ***-* *

Chapter IV Priming with DNA and Boosting with Vaccinia Virus (VACV) Expressing
GP5-Mosaic Vaccine Confers Cross-Protection Against Heterologous PRRSV Strains in
Pigs

Summary
A GP5-Mosaic T-cell vaccine, designed and developed in our laboratory as a DNA vaccine and
recently tested, induced cross-reactivity ex-vivo in recall-stimulated peripheral blood
mononuclear cells (PBMCs) and conferred partial protection in vaccinated pigs. The present
study follows up on these results, where priming with an rDNA GP5-Mosaic and boosting with a
recombinant Tet-inducible Vaccinia virus GP5-Mosaic (rVACV-GP5-Mosaic) followed by
heterologous virus challenge was performed in pigs to test further whether the GP5-Mosaic
vaccine cross-protected pigs. The rDNA GP5-Mosaic vaccines were administered by
intramuscular (IM) injection along with Quil-A® as an adjuvant. The pigs received a boost of
rVACV-GP5-Mosaic by IM injection three weeks later. Blood was collected periodically and
tested for vaccine-induced responses. In samples collected at challenge day, the expression of
interferon-γ (IFN-γ) mRNA in VR2332 or MN184C stimulated PBMNC of GP5-Mosaicvaccinated pigs was significantly higher as compared to those of VR2332 GP5 (GP5-WT) or
empty vector-vaccinated control pigs. In GP5-WT-vaccinated pigs, such responses were
recorded only upon VR2332 stimulation (p<0.05). In addition, the levels of virus-specific
antibodies were higher in GP5-Mosaic-vaccinated pigs than those of control pigs. Moreover,
these antibodies were neutralizing. The GP5-Mosaic-vaccinated pigs were cross-protected from
heterologous strains as demonstrated by significantly lower viral loads in sera, tissues, alveolar
macrophages (PAMs), and bronchoalveolar lavage (BAL) fluids and lower lung lesion scores
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(p<0.05) upon challenge with either MN184C or VR2332. Under the same criteria, the pigs
receiving GP5-WT vaccination showed protection only against challenge with VR2332 when
compared to the vector-control group. This data demonstrates that the GP5-Mosaic vaccine
induced both humoral and cellular responses and conferred cross-protection against heterologous
strains in pigs.

Key words: PRRS, PRRSV, mosaic T-cell vaccine, VACV, cross protection, heterologous
challenge

1. Introduction
Porcine reproductive and respiratory syndrome viruses (PRRSV) rapidly spread across
the world in all major pork-producing countries, causing significant economic losses to swine
industries. For instance, in the United States alone, PRRS, costs more than $660 million to pork
producers annually (1). PRRS is characterized clinically by reproductive failure in pregnant sows
and respiratory diseases in pigs at all ages, especially the young. PRRSV is a positive-sense,
single-stranded RNA virus with an enveloped virion that belongs to the family of Arteriviridae
of the order Nidovirales (2)(3)(4). The viral genome is approximately 15 kb in length and
encodes at least 22 different viral proteins including 14 non-structural and 8 structural proteins
(5). Some viral proteins have been shown to induce humoral and/or cell-mediated immune
responses in infected pigs, but none of those have been shown to provide complete immune
protection (6)(7)(8)(9). Vaccines against PRRS including modified live virus (MLV) vaccines
and killed virus (KV) vaccines have been licensed for more than two decades. Although the
efficacy of MLV vaccines is generally better to that of KV vaccines (10)(11)(12)(13), it is very
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unwise to ignore the fact that the levels of protection against heterologous PRRSV strains are
highly variable and generally considered sub-optimal (10)(14)(15)(16)(17)(18). Additionally of
great concern is the potential reversion of MLVs to virulence (19)(20)(21).
The extremely high genetic variation of PRRSV genome is the major challenge to the
development of PRRS vaccines that confer adequate cross-protection. PRRSV is classified into 2
major genotypes, Genotype I (EU) and Genotype II (NA), which show up to 40% dissimilarity
on sequence identity (22)(23). Moreover, Genotype I and Genotype II can be further sub-divided
into 4 subgroups and 9 different lineages, respectively, based on phylogenetic analysis of the
ORF 5 (24). The co-existence of multiple variants within one farm, among animals, or even
within individuals possibly indicates a level of quasispecies variation of PRRSV (25). Numerous
studies have been conducted to improve the vaccine capacity aiming at inducing effective crossprotection including multi-subunit vaccines (26), consensus vaccines (27), molecular breeding of
different structural proteins (28), and mosaic T-cell vaccines (29). In addition to those mentioned
above, a polyvalent vaccine containing five different live-attenuated PRRSV strains has been
tested in pigs. However, this effort has not provided a significant improvement with regard to
heterologous protection (30).
As clearly demonstrated in the field of human immune deficiency virus type 1 (HIV-1)
vaccine research, the use of mosaic sequences that are made of natural peptide residues could
effectively address the genetic diversity issue (31)(32). Mosaic vaccines have been shown to
successfully elicit broader immune responses and confer cross-protection in non-human primates
that eventually moved into human trials (33)(34)(35). We described previously the development
and characterization of a GP5-Mosaic vaccine based on 748 Type II PRRSV strains (29). The
GP5-Mosaic vaccine was immunogenic, induced cross-reactivity ex-vivo in PBMCs to 4
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divergent Type II PRRSV strains with at least 10% difference in GP5 sequence and conferred
protection in pigs (Cui et al. manuscript in preparation). Herein, we show that vaccination of pigs
with the GP5-Mosaic vaccine confers heterologous protection against divergent PRRSV strains
while the GP5-WT vaccine does not.

2. Materials and Methods
2.1. Viruses and Cells

MN184C was kindly provided by Drs. Kay Faaberg and Kelly Lager from USDA ARS.
Viruses were propagated in MARC-145 cells (36). The cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM Lglutamine, 100 U penicillin/mL, and 100 µg streptomycin/mL. Virus titers were calculated by
the Reed and Muench method (37). The viruses were purified over continuous cesium chloride
gradients, quantified using a spectrophotometer NanoDrop 1000 (Thermo Scientific) and stored
at -80°C for future use. Purified VR2332 was used as antigen for indirect ELISA. Titrated
viruses were used for neutralization assay, recall immune response assay and challenge.

2.2. Transfer Vector Construction

Three transfer vectors were generated by a combination of gene synthesis (DNA2.0,
Menlo Park, CA) and standard subcloning. Each transfer vector contained a cassette consisting
of the tetR gene (based on GenBank: X00694), as well as either a natural or mosaic version of
PRRSV Genotype II ORF 5 (29), followed by the EMCV IRES (based on GenBank:
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NC_001479.1) and the EGFP gene (based on plasmid pEGFP-1, GenBank: U55761). The tetR
gene and the ORF 5–IRES-EGFP genetic segment were placed under back-to-back synthetic
VACV early/late promoters (38). The tetO2 operator sequence was inserted after the putative
VACV D6R promoter as described in (39). The cassettes were flanked by 600 bp of the VACV
D5R gene to the left and 600 bp of the VACV D6R gene to the right (based on GenBank:
NC_006998.1). Plasmid identity was confirmed by restriction endonuclease analysis.

2.3. Generation of Recombinant VACVs and Preparation of High-titer Stocks

Tetracycline-inducible recombinant VACVs were generated by standard homologous
recombination after transfection of transfer vectors with FuGene HD Transfection Reagent
(Promega, Madison, WI) into BS-C-1 cells infected 1 hour previously with an IPTG-inducible
VACV strain (based on the WR clone 9.2.4.8.) in the presence of 0.1 mM IPTG and 1 µg/mL
doxycycline. Recombinant EGFP-positive, tetracycline-inducible VACVs were plaque purified
in the absence of IPTG and presence of 1 µg/mL doxycycline. Elimination of parental virus was
confirmed by PCR analysis of viral DNA purified using a Nucleospin® Blood kit (MachereyNagel, Düren, Germany). High-titer stocks were generated by infecting HeLa S3 cells with
recombinant virus at an MOI of 0.1 in the presence of 1 µg/mL doxycycline. Infected cells were
harvested and homogenized 4 days post-infection. Homogenates were clarified by centrifugation
at 750 x g for 10 min, purified by sucrose cushion (40), and resuspended in 1xPBS pH 7.3 (with
no doxycycline).

2.4. Protein Sequence Alignment and Phylogenetic Analysis
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The protein sequence alignments between GP5 sequences of VR2332, MN184C, Mosaic
1 and Mosaic 2 and phylogenetic tree were evaluated using MEGA 7 (Molecular Evolutionary
Genetics Analysis) (www.megasoftware.net).

2.5. Vaccination and Collection of Samples

Three to four-week-old, PRRSV-free, porcine circovirus-2-free, cross-bred piglets were
used in this study. The experimental design is shown as Table 4.1, and each pig is considered as
one experimental unit. The vaccination scheme consisted of priming with rDNA vaccines
previously constructed (29), followed by rVACV boosts. The GP5-Mosaic, GP5-WT, and
vector-control vaccines were administered using both intradermal (ID) and intramuscular (IM)
injection. Briefly, 0.1 mL GP5-Mosaic, GP5-WT, or vector-control vaccine containing 500 μg
DNA/mL and 100 μg Quil-A®/mL as an adjuvant was injected ID on the back of the ear and 0.9
mL IM in the neck musculature at day 0 and boosted once at day 14. Then the animals were
boosted via IM injection in the neck musculature with 1 mL solution containing 108 PFU
rVACV- GP5-Mosaic, rVACV-GP5-WT, or VACV itself, and 100 μg Quil-A® as an adjuvant at
day 28. Virus challenge was given at day 35 with VR2332 and day 37 with MN184C and
necropsies were performed 14 days post-challenge. The challenge virus was given both
intranasally and intramuscularly, with a total of 106 TCID50/pig. Blood samples were collected at
days 0, 7, 14, 21, 28, the challenge day, and 4, 7, 10, and 14 days post-challenge as shown in
Scheme 4.1. At the end of the experiment, the pigs were euthanized, and the lungs were
evaluated macroscopically, weighed, and bronchoalveolar lavages (BAL) were performed.
Tissue samples were collected from each lung lobe, tracheobronchial lymph nodes (TBLN),
spleen, inguinal lymph nodes (ILN) and tonsils and then fixed in 10% neutral buffered formalin
92

or kept frozen. Fixed tissues were sectioned, and stained with hematoxylin and eosin for
histologic evaluation. Lung lesion scores were evaluated as previously reported (41). All the
animal work was done under a protocol approved by the University of Connecticut Institutional
Animal Care and Use Committee.

2.6. Cytokine Recall Cellular Response to PRRSV

PBMCs isolated at days 0 and challenge day were seeded in 24-well flat-bottom plates
(5x105 cells/well) in duplicate and were stimulated with 200 TCID50 VR2332 or MN184C /well
or mock control for 48 h at 37°C in a 5% CO2 atmosphere. The cells were collected, and total
RNA was extracted for quantitative real-time PCR analysis of IFN-γ.

2.7. Indirect Enzyme-Linked Immunosorbent Assay

ELISA was performed as described previously (29). Briefly, purified VR2332 was coated
overnight at 4°C onto 96-well plates at a concentration of 2.5 µg/mL, and the plates were
blocked with 10% dry milk in PBS-T (PBS containing 0.05% Tween-20) for 2 h at room
temperature. The plates were washed with PBS-T twice and sera samples diluted 40-fold in PBST buffer containing 5% dry milk was added. After 60 min at room temperature, the plates were
washed five times with PBS-T buffer and incubated with mouse HRP anti-pig IgG (The Jackson
Laboratory, Bar Harbor, ME) for 60 min at room temperature. The plates were washed five times
in PBS-T, substrate was added, and the plates were incubated in the dark at room temperature for
15 min. The reactions were stopped with 1 M HCl solution. The plates were read at OD450 in a
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microplate reader (Biotek HTK model, Winooski, VT). Archival PRRSV positive and negative
sera of pigs were used as controls in each run.

2.8. Serum Neutralization

Serum neutralization tests were performed as reported previously (29). Briefly, test sera
were mixed with equal volumes of DMEM containing 100 TCID50 of VR2332 or MN184C (final
serum dilution 1:4). After incubation at 37°C for 1 h, the sera-virus mixtures were added to
MARC-145 monolayers in 96-well plates, and incubated at 37°C in a 5% CO2 atmosphere for 48
h. VR2332 or MN184C virus plus negative serum and uninfected cells were used as virus and
cell controls, respectively. Neutralization was quantified both by a fluorescence intensity
reduction (FIR) test and qRT-PCR 48 h after infection. For FIR, cells 48 h after infection were
washed three times with PBS and then fixed with 80% cold acetone for 15 min at 4°C. The cells
were reacted with a protein-A purified PRRSV-positive swine serum for 1 h. After three washes
with PBS, FITC-conjugated rabbit anti-pig IgG (Sigma, St. Louis, MO) was incubated for 1 h.
After washing, fluorescence intensity was measured in a microplate reader (Biotek HTK model,
Winooski, VT).

2.9. Quantitative Real-time PCR

Total RNA was extracted from 250 µL of serum or supernatants using TRIzol LS
Reagent or from tissues using TRIzol Reagent (Invitrogen, Grand Island, NY). RNA was
quantified using a spectrophotometer NanoDrop 1000 (Thermo Scientific). cDNA was
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synthesized using random primers (Invitrogen, Grand Island, NY) in a 20 µL reaction mixture.
The reaction was run in a thermocycler (Applied Biosystems GeneAmp PCR System 2400) as
follows: 26°C for 10 min, 42°C for 45 min and 75°C for 10 min. SYBR Green real-time PCR
was then performed, SYBR qPCR Master Mix was purchased from Bimake (Bimake, Houston,
TX), and the cDNA was used as a template with 5’-ATG ATG RCC TGG CAT TCT- 3’and 5’ACA CGG TCG CCC TAA TTG- 3’ as the forward and reverse primers for ORF7, respectively.
The PCR reaction was performed at 95°C for 2 min, followed by 40 cycles of 95°C for 15 s and
61°C for 1 min using Bio-Rad CFX96 Touch System (Bio-Rad, Hercules, CA). For each assay, a
standard curve was generated using serially diluted RNA which contained 102–107 copies/μL. In
each run, positive and negative reference samples were run along with the test samples. The viral
loads were determined by plotting the Ct values against the standard curve. Melting curves were
analyzed to verify the specificity of the PCR.
For cytokine evaluation, total RNA was extracted from virus-stimulated or mock-treated
PBMCs using TRIzol Reagent. cDNA synthesis and real-time PCR followed the same protocol
described above. GAPDH (forward primer: 5’-CGT CCC TGA GAC ACG ATG GT- 3’and
reverse primer: 5’-CCC GAT GCG GCC AAA T -3’) was used as internal control to calculate
the changes of IFN-γ (forward primer: 5’-TGG TAG CTC TGG GAA ACT GAA TG - 3’and
reverse primer: 5’- GGC TTT GCG CTG GAT CTG -3’) or Interleukin-10 (IL-10) (forward
primer: 5’- TGA GAA CAG CTG CAT CCA CTT C- 3’and reverse primer: 5’-TCT GGT CCT
TCG TTT GAA AGA AA -3’) by the delta-delta method (42).

2.10.

Lung Lesion Scoring
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Lung lesion scoring was done by a board certified veterinary pathologist, blinded to the
treatment groups as previously described (41).

2.11.

Statistical Analysis

Student t-test or Two-way ANOVA was used to evaluate the differences between the
samples within or between groups. The data were analyzed using GraphPad Prism (version 7.0).

3. Results
3.1. Sequence Alignment and Analysis of GP5

The GP5 amino acid (aa) sequences of Mosaic 1, Mosaic 2, MN184C, and VR2332, the
prototype of Type II PRRSV strains, were of the same size and with no deletions or insertions.
Sequence alignments showed that aa identities ranged from 85 to 93%. To further investigate the
antigenic relationship of these strains, phylogenetic trees were built using neighbor-joining
method based on the aa sequences of the two mosaics, VR2332 and MN184C. The four
sequences could be roughly categorized into two subgroups (Fig. 4.1), and the two far ends were
represented by Mosaic 1 and MN184C. Mosaic 1 and Mosaic 2 were closely related to VR2332
and MN184C respectively. VR2332 shared high aa identity with Mosaic 1 and MN184C shared
high aa identity with Mosaic 2.

3.2. GP5-Mosaic Vaccines Activated Both Humoral and Cellular Responses
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GP5-Mosaic vaccines induced broad recall cellular responses as detected by the
significantly higher levels of IFN-γ mRNA relative fold-change shown in Fig.4.2. Significantly
higher levels of IFN-γ mRNA expression were detected upon stimulation of PBMCs of GP5Mosaic-vaccinated pigs with both VR2332 and MN184C as compared to those in mock controls
(p<0.05). The response was only significantly higher in IFN-γ mRNA expression in VR2332stimulated PBMCs of pigs vaccinated with GP5-WT- at the same time points compared to those
in mock controls. No such change was detected in those of vector-control pigs.
The vaccination with the GP5-Mosaic vaccine induced significantly higher levels of
antibodies, as detected in sera collected at challenge day (p<0.05) than those of vector-control
animals. Such effects were detected in sera of GP5-WT-vaccinated pigs at the same time points
compared to those of vector-control animals (p<0.05). Furthermore, sera collected at challenge
day from GP5-Mosaic-vaccinated pigs neutralized virus (Figs. 4.2C). The levels of neutralizing
antibodies in sera from GP5-Mosaic-vaccinated pigs were higher compared to those in sera from
vector-control animal (Fig. 4.2C) as shown by significantly lower viral copy numbers in seraVR2332 mixture (p<0.0001) and srea-MN184C mixture (p<0.05), compared to those pigs
receiving vector-control. The ability to induce neutralizing antibodies was detected in GP5-WTvaccinated animals only mixed with VR2332 but not with MN184C.

3.3. Vaccination Did Not Significantly Affect Rectal Temperatures of Experimental Pigs

Rectal temperatures showed a very similar pattern in all groups with VR2332 challenge;
there were two peaks at 7DPC and 11DPC in vector-control pigs (Fig. 4.3. top). Rectal
temperatures of GP5-Mosaic-vaccinated pigs were generally lower than those in vector-control
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pigs and no peak observed while there were two peaks observed at 4DPC and 8DPC with
MN184C challenge (Fig. 4.3. bottom).

3.4. GP5-Mosaic Vaccination Induced Cross-protection in Pigs

Viral loads in sera of both GP5-WT and GP5-Mosaic-vaccinated pigs were significantly
lower than those of vector-control pigs at 7, 10 and 14 DPC with VR2332 (p<0.05*, p<0.01**).
The GP5-Mosaic vaccine showed comparable capability of reducing viral loads in sera compared
to the GP5-WT vaccine. Viral loads in sera of pigs challenged with VR2332 steadily decreased
from 4 to 14 DPC in both GP5-WT and GP5-Mosaic-vaccinated pigs while viral loads increased
after challenge and reached its peak at 10 DPC, then slightly declined at 14 DPC in sera of
vector-control pigs (Fig.4.4A). In contrast, viral loads in sera of GP5-Mosaic-vaccinated pigs
were significantly lower than those in both GP5-WT and vector-control pigs at 7 and 14 DPC
with MN184C (p<0.05*). Viral loads in sera in pigs vaccinated with GP5-WT showed a similar
pattern as the vector-control pigs but in lower levels, they increased during the infection and
reached peak at 10DPC with MN184C, compared to the vector-control pigs. The viral loads in
pigs vaccinated with GP5-Mosaic-vaccine and challenged with MN184C steadily decreased from
4 to 10 DPC, then stayed with no changes up to 14 DPC (Fig.4.4B).
Viral loads in tissues including lung, TBLN, spleen, ILN, and tonsils of GP5-Mosaicvaccinated pigs were significantly lower than those of vector-control pigs (p<0.05) after
challenge with MN184C, while those of GP5-WT-vaccinated pigs were similar or slightly lower
compared to those of vector-control pigs (Fig.4.5A). Viral loads in tissues including lung, TBLN,
and tonsil of pigs vaccinated with GP5-Mosaic-vaccine were significantly lower than those of
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vector-control pigs (p<0.05) after challenge with VR2332, while those of GP5-WT-vaccinated
pigs were considerably lower in lung, spleen, and ILN compared to vector-control pigs (p<0.05).
No significant differences in tissue virus loads between GP5-Mosaic and GP5-WT vaccination in
pigs were found (Fig. 4.5B).
Viral loads in PAMs and BAL fluids showed very a similar pattern in which only those of
GP5-Mosaic-vaccinated pigs were significantly lower than those of vector-control pigs with
MN184C challenge (p<0.05* and p<0.01**), while there was no difference between those of
GP5-WT and vector-control pigs (Fig. 4.6B, 4.7B). The viral loads in PAMs or BAL of both
GP5-Mosaic and GP5-WT-vaccinated pigs were lower than those of vector-control pigs after
VR2332 challenge (Fig. 4.6A, 4.7A).

3.5. Lower Lung Lesion Scores Detected in GP5-Mosaic-vaccinated Animals

Lung lesion scores were significantly lower in GP5-Mosaic-vaccinated animals than
those in both GP5-WT and vector-control animals when 9 sections of lung were scored after
MN184C challenge (Fig. 4.8. right panel, p<0.05). The lung lesion scores were lower but not
statistically significant in both GP5-Mosaic and GP5-WT-vaccinated pigs, compared to those of
vector-control animals after VR2332 challenge. No differences were observed between GP5-WT
and GP5-Mosaic-vaccinated pigs (Fig. 4.8, left panel).

4. Discussion
In attempts to effectively address the extraordinary diversity of PRRSV, numerous
studies have been reported (29)(28)(43)(44). Recently, several studies including a synthetic
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consensus PRRSV strain (27), chimeric PRRSV strain containing shuffled multiple ORFs (45),
and an intranasal live virus vaccine with adjuvant (46) showed the capacity of inducing certain
levels of heterologous protection in pigs. However, these vaccines are modified live virus
vaccines. In addition to the safety concerns, the major drawback of the currently available MLV
vaccines is that they are unable to address the great diversity issue of PRRSV and thus cannot
provide adequate levels of cross-protection (47). An alternative approach holding great promise
is the mosaic T-cell epitope vaccine strategy (31). There is mounting evidence with HIV, another
hyper-variable RNA virus, that mosaic T-cell epitope-based vaccines increase the vaccine’s
breadth and depth and thus broaden the coverage (34)(35) that provides a great potential to
effectively deal with the problem of genetic diversity. We have previously demonstrated that
GP5-Mosaic vaccine was immunogenic, induced cross-reactivity ex-vivo, and conferred partial
protection in pigs (29)(Cui et al. manuscript in preparation). The potential of the GP5-Mosaic
vaccine to provide cross-protection against heterologous PRRSV strains was further investigated
and proven in the present study.
To test the capacity of GP5-Mosaic vaccine to induce cross-protection in pigs, two
PRRSV strains were comprehensively compared and meticulously selected as challenge viruses.
VR2332, the prototype of Genotype II PRRSV that is also the parental strain for several
commercial MLVs, belongs to lineage 5 and MN184C, a strain with high virulence, belongs to
lineage 1 (24). These two strains show 15% difference in GP5 aa sequence. Therefore, VR2332
and MN184C were very representative for Type II PRRSV and used in this heterologous
protection study. Computer-based assessments are commonly used to predict epitopes, evaluate
epitopic coverage or genetic/ antigenic relationships in vaccine development or virus evolution
(48)(31)(27)(24). Under such circumstance, two GP5-Mosaic sequences, VR2332 and MN184C
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were used to generate a phylogenetic tree using the neighbor-joining method to establish their
relationship with regard to genetic diversity. Interestingly, GP5-Mosaic 1 was closer to VR2332
(93% aa identity), while GP5-Mosaic 2 was closer to MN184C (90% aa identity). This indicates
that the two GP5-Mosaic sequences showed broader coverage spanning strains belonging to
different lineages. Therefore, broader immune responses and cross-protection could be expected
when pigs vaccinated with GP5-Mosaic vaccine were challenged with either VR2332 or
MN184C. The VR2332 and MN184C share only 85% in GP5 aa identity between them making
this challenge heterologous (Fig. 4.1).
In order to enhance vaccine efficacy, Quil-A® was used as adjuvant in this study to
increase the host’s immune responses as reported before (49)(50)(51). Furthermore, the DNA
prime/vaccinia boost regimen has already been shown to greatly increase the vaccination
efficacy (52)(53). In addition, VACV vector is very attractive for the development of vaccines
including animal vaccines, human vaccines and cancer immunotherapy (54). Thus, in this study,
a GP5-Mosaic DNA prime/ VACV-GP5-Mosaic boost vaccination regimen was an appropriate
choice to test the vaccine efficacy, in terms of cross-protection. The immune responses induced
by GP5-Mosaic vaccine were consistent with Th1 responses with higher levels of IFN-γ, which
were reported to play a critical role in the control of PRRSV infection (55). Moreover, evidence
was recorded such as both humoral and cellular responses were activated in GP5-Mosaicvaccinated pigs in this study as demonstrated by steadily increasing antibodies after
immunization (Fig. 4.2B) and higher levels of neutralizing antibodies before challenge (Fig.
4.2C). Vaccination induced higher levels of IFN-γ mRNA expression upon stimulation with
either VR2332 or MN184C at challenge day (Fig. 4.2A). This demonstrated that GP5-Mosaic
vaccine-induced cross-reactivity was consistent with a previous study (Cui et al, manuscript in
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preparation) which predicted the ability to induce cross-protection in pigs. In contrast, PBMCs
isolated from pigs vaccinated with GP5-WT only responded to stimulation with VR2332. The
use of GP5-Mosaic vaccine as a cocktail of Mosaic 1 and Mosaic 2 may explain, in part, the
broadening in epitope coverage of Type II GP5 sequences.
Body temperature, lung lesion scores, and the PRRSV viral loads in sera, lung and other
tissues such as TBLN, ILN, spleen, and tonsils (after challenge) are the most frequently used
assessments for evaluating PRRS vaccine protective efficacy (56)(10)(57)(58). In general, higher
body temperature was expected in the control pigs compared to the vaccinated/challenged pigs.
As expected when challenged with MN184C virus, GP5-Mosaic-vaccinated pigs had a lower
body temperature mean, while vector-control pigs developed higher body temperature in the
same period with two peaks at 4DPC and 8DPC. The positive control, GP5-WT-vaccinated pigs,
displayed a body temperature curve between those of GP5-Mosaic and vector-control pigs with
smaller peaks at 6DPC and 10DPC (Fig. 4.3B). When challenged with VR2332, both GP5Mosaic and GP5-WT-vaccinated pigs showed similar body temperature curves with a peak at
9DPC while two peaks at 7DPC and 11DPC were recorded in vector-control pigs (Fig. 4.3A). A
possible explanation is that MN184C is more virulent than VR2332. Therefore, pigs with
MN184C challenge developed higher and earlier peak temperature with around 104°F at 4DPC
and 8DPC while pigs with VR2332 challenge displayed lower and later peak temperature with
around 103°F at 7DPC and 11DPC in vector-control pigs.
As an important protection measure, viral loads in sera of both GP5-Mosaic and GP5WT-vaccinated pigs showed significantly lower levels at 7, 10 and 14DPC than those of vectorcontrol pigs after VR2332 challenge. In contrast, after MN184C challenge only pigs vaccinated
with the GP5-Mosaic-vaccine had significantly lower viral loads in sera at 7DPC and 14DPC
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than the vector-control pigs (Fig. 4.4). This piece of evidence demonstrated that the GP5-Mosaic
vaccine was able to clean circulating viruses in pigs in either challenge while the GP5-WT
vaccine was only able to clean homologous virus circulating in pigs. Furthermore, a similar
pattern was recorded in tissues where GP5-Mosaic-vaccinated pigs displayed significantly lower
viral loads in lung, TBLN, spleen, ILN, and tonsils, compared to those of vector-control pigs
with MN184C challenge, while GP5-WT-vaccinated pigs only showed slightly lower but not
significantly lower viral loads. Additionally, lower viral loads in PAMs or BAL fluid were
recorded in GP5-Mosaic-vaccinated pigs. Lung lesion score is an essential and crucial method to
evaluate the effects of PRRSV infection, including enhancing the susceptibility to coinfection
with other pathogens namely, viral or bacterial pathogens (59)(60)(61). GP5-Mosaic-vaccinated
pigs, not surprisingly, showed significantly lower lung lesion scores than both the GP5-WT and
vector-control pigs after challenge with the MN184C strain. In contrast, pigs vaccinated with
either GP5-Mosaic or GP5-WT showed lower, although not significant, lung lesion scores
compared to the vector-control pigs after challenge with VR2332. Moreover, atrophic rhinitis
(AR), a common respiratory infection of piglets, was recorded in some of the vector-control pigs
but not in any of the GP5-Mosaic-vaccinated pigs. Together, our results strongly demonstrate
that GP5-Mosaic vaccine was able to clean both circulating and local heterologous viruses, thus
clearly providing cross-protection against challenge with two heterologous PRRSV strains
including VR2332, the prototype Genotype II strain, and MN184C, a highly virulent strain.
Over the course of this study, we successfully demonstrated that the GP5-Mosaic vaccine
was able to provide cross-protection against heterologous PRRSV strains in pigs with the
contributions from both arms of the immune system, humoral and cell-mediated immune
responses. Additionally, we demonstrated that the GP5-Mosaic vaccine is a viable approach to
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generate novel vaccines with enhanced cross-protection abilities against diverse PRRSV strains.
In the future, components such as other PRRSV structural and non-structural proteins containing
T-cell epitopes will be incorporated into multivalent, multiepitopic mosaic vaccine to further
enhance efficacy and improve cross-protection.
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Figure 4.1. Phylogenetic Analysis Based on Amino Acid Sequences of GP5 of Two Mosaic
Sequences, MN184C and VR2332. The analysis was done using neighbor-joining method of
MEGA7.0.
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Table 4.1 Experimental Design
Group

Immunizationa

A(n=8)

Vector-control

B(n=8)

GP5-WT

C(n=8)

GP5-Mosaic

Challengeb
VR2332
MN184C
VR2332
MN184C
VR2332
MN184C

a

1 mL vaccine containing 500 μg DNA and 100 μg Quil-A® as adjuvant was injected intradermally (0.1
mL) on the back of ear and intramuscularly (0.9 mL) on the neck musculature at day 0 and boosted once
at days 14. 10E8 PFU VACV and 100 μg Quil-A® as an adjuvant boosted at day 28.
b

Pigs were challenged at day 35 with 106TCID50 VR2332 and day 37 with 106TCID50 MN184C via both
intranasal and intramuscularly. All groups had equal numbers of male and female pigs
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Vaccination Boost

0

7

14

21

VACV
Boost

Heterologous
Challenge

28

35

Necropsy

7dpc

4dpc

Blood
collection

14dpc

10dpc

Scheme 4.1. Vaccination/Challenge Design. Blue arrows indicate the major operations
including vaccination, boost, challenge, and necropsy. Red arrows indicate blood sample
collections.
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Figure 4.2. Vaccine-induced Humoral and Cellular Responses. A. Virus-specific antibodies
detected by iELISA over time. B. Changes in viral copy numbers induced by serum antibodies
detected in infected cell supernatants by qRT-PCR. Each dot represents the mean value of each
animal. Each bar represents the mean value of each group. Variation expressed as standard error
of the mean. Three experiments were performed independently. Significant differences
calculated by a Two-way ANOVA or student t-test (p<0.05* or p<0.001***).
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Figure 4.3. Rectal Temperature of Pigs Comparison between Immunization Groups after
Heterologous Challenge. Top. Rectal temperatures changes post VR2332 challenge. Bottom.
Rectal temperatures changes post MN184C challenge. Each dot represents the mean value of
each group. Variation expressed as standard error of the mean. Experiments were performed
independently. Significant differences calculated by a student t-test (DPC: days post challenge)
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Figure 4.4. Virus Clearance in Sera. A. Comparison of viral copy numbers in serum from 0
DPC to 14 DPC upon VR2332 challenge. B. Comparison of viral copy numbers in serum from 0
DPC to 14 DPC upon MN184C challenge. Each dot represents the mean value of each group.
Variation expressed as standard error of the mean. Three experiments were performed
independently. Significant differences calculated by a Two-way ANOVA or student t-test
(p<0.05*, p<0.01**, DPC: days post challenge).
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Figure 4.5. Virus Clearance in Tissues. A. Viral copy numbers in tissues at necropsy upon
VR2332 challenge. B. Viral copy numbers in tissues at necropsy upon MN184C challenge. Each
bar represents the mean value of each group. Variation expressed as standard error of the mean.
Three experiments were performed independently. Significant differences calculated by student
t-test (p<0.05*).
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Figure 4.6. Virus Clearance and Lung Lesion Scores. A. Viral copy numbers in BAL fluids at
necropsy upon VR2332 challenge. B. Viral copy numbers in BAL fluids at necropsy upon
MN184C challenge. Each bar represents the mean value of each group. Variation expressed as
standard error of the mean. Three experiments were performed independently. Significant
differences calculated by a student t-test (p<0.05*).
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Figure 4.7. Virus Clearance in PAMs. A. Viral copy numbers in PAMs at necropsy upon
VR2332 challenge. B. Viral copy numbers in PAMs at necropsy upon MN184C challenge. Each
dot represents the mean value of each animal. Variation expressed as standard error of the mean.
Three experiments were performed independently. Significant differences calculated by a student
t-test (p<0.05*, p<0.01**).
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Figure 4.8. Lung Lesion Scores. Lung lesion scores. Scores were significantly lower (p<0.05)
in GP5-Mosaic-vaccinated animals than those in vector-control animals. Each dot represents the
mean value of each individual. Variation expressed as standard error of the mean. Three
experiments were performed independently. Significant differences calculated by a student t-test
(DPC: days post challenge).
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